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Viruses usurp host cell pathways for different stages of their infection. 
Understanding virus-host interaction will be invaluable to elucidate molecular 
mechanisms of virus infection and to identify drug targets. In order to identify such 
critical cellular genes in vesicular stomatitis virus (VSV, a model non-segmented 
negative strand RNA virus) infection, we developed a stable cell line constitutively 
expressing replication proteins of VSV. Attempts to establish a cell line replicating a sub-
genomic replicon was not successful because of induction of interferon response by 
replication of viral genomic analog. Subsequently, we used siRNA technology and 
conducted a genome-wide siRNA screen in HeLa cells to identify host factors regulating 
VSV infection. A total of 23,000 human genes were knocked down individually, and 
their effect on viral infection was interrogated using a high-throughput cell-based assay. 
Our study identified several previously unknown host proteins required for VSV 
infection.  Bioinformatics analysis predicted enrichment of several biological functions 
among these proteins and some of them are commonly utilized by other pathogens such 
as human immune deficiency virus (HIV), hepatitis C virus (HCV) and Influenza virus. 
We also noted that 35% of these genes (25 out of 72) are required for lymphocytic 
choriomeningitis virus (LCMV) and human parainfluenza virus type 3 (HPIV3) infection, 
suggesting evolutionary conserved mechanisms of virus-host interactions. Further studies 
 focusing on host coatomer complex 1 (COPI) identified a role of COPI in early stage of 
VSV infection. The effect of COPI is mediated at the level of viral RNA synthesis. COPI 
functions are required not only for VSV but also for LCMV and HPIV. ADP ribosylation 
factor 1 (ARF1), the immediate upstream modulator of COPI was found as a required 
factor for VSV RNA synthesis. ARF1 is activated by the Golgi-associated brefeldin A 
resistant guanine nucleotide exchange factor 1 (GBF1) which was found to be a critical 
determinant of VSV RNA synthesis.  These studies suggested that the components of the 
cellular secretory pathway are required for VSV RNA synthesis.  
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Chapter I 
INTRODUCTION 
1.1 Significance of vesicular stomatitis virus as a model pathogen 
Vesicular stomatitis virus belongs to the family Rhabdoviridae and order 
Mononegavirales. It is an enveloped virus with a negative-stranded RNA genome of 
11,161 nucleotides (Lyles and Rupprecht, 2007). Members of the Rhabdoviridae family 
can infect animals, plants as well as insects. VSV spreads between ungulates and rodents 
via insect vectors. Arthropod vectors such as flies and mosquitoes transmit VSV in 
natural or laboratory conditions. VSV causes a self- limiting disease termed “vesicular 
stomatitis” in cattle, horse and pigs. Vesicular stomatitis is rarely fatal but is associated 
with significant economic loss to live stock producers. Infection in humans by VSV is 
asymptomatic. Mild flu like symptoms has been reported after VSV infection.  
VSV has served as an excellent model pathogen to study fundamental aspects of 
virus biology and viral pathogenesis. Discovery of RNA dependent RNA polymerase 
(RdRp) in VSV  (Baltimore et al., 1970) led to the classification of single-stranded RNA 
viruses into positive-and negative-strand RNA viruses. VSV can infect almost all 
vertebrate cells and many invertebrate cells and has a short infection cycle. These 
characteristics have earned appreciation for VSV as an excellent model virus to study 
virus entry, replication and virus budding as well as innate and adaptive immune defense 
mechanisms. In fact, much of our current understanding about negative strand RNA 
viruses has come from studies with VSV. The cell-free system provided a major tool to 
study virus transcription and replication as well as RNA encapsidation (Emerson & Yu, 
1975). Sequential nature of transcription and single polymerase entry site has been 
demonstrated using the cell-free reconstitution system with VSV (Emerson, 1982; 
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Iverson & Rose, 1981). VSV glycoprotein has been widely used in cell biology to probe 
the secretory pathways (Bonifacino & Lippincott-Schwartz, 2003). Because of the error 
prone nature of VSV polymerase and short life cyle, VSV also serves as an elegant model 
to study virus evolution (Novella, 2003).  
Absence of a suitable system for direct manipulation of genomes of negative 
strand RNA viruses was a major hurdle in the advancement of the field till early 1990s. 
Reverse genetic system for manipulation of a negative strand RNA virus genome was 
initially established using VSV defective interfering particles (Pattnaik et al., 1992).  
Based on this approach, infectious rabies virus and VSV were subsequently recovered 
from cDNA clone (Lawson et al., 1995; Schnell et al., 1994; Whelan et al., 1995). The 
reverse genetic system for VSV is a powerful tool to dissect the cis- and trans- acting 
elements on VSV genome replication and transcription.  Much of our understanding of 
the roles of leader, trailer, and intergenic gene junction for non segmented negative strand 
viruses has been derived using VSV as a model (Hwang et al., 1998; Li & Pattnaik, 1999; 
Pattnaik et al., 1995; Stillman & Whitt, 1997; 1998; Wertz et al., 1994; Whelan et al., 
2000; Whelan & Wertz, 1999b).   
 In the 21
st
 century research using VSV as a model has taken a new dimension. 
The observation that VSV replicates well in transformed cell line but its replication is 
attenuated in primary cells led the way to use VSV as a selective anti-tumor agent 
(Barber, 2005; Lichty et al., 2004). Excellent reverse genetic system to manipulate VSV 
genome to develop a better oncolytic agent has given significant impetus to tumor 
therapeutics. With the advancement modern molecular biology tools, the researchers have 
begun to use VSV as a vaccine vector. Vaccines based on live attenuated VSV are 
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effective in animal models.  Strains of VSV that induces interferon response have also 
been in use as potential vaccine platform.  For over four decades, research using VSV has 
made a significant impact on many aspect of basic virology. The ongoing research using 
VSV as model virus still holds the promise for exciting discoveries in the coming years.   
1.2 Classification of VSV 
VSV belongs to the family Rhabdoviridae and the genus Vesiculovirus. It is 
placed in the order Mononegavirales. The order Mononegavirales comprises of four 
families namely Rhabdoviridae, Paramyxoviridae, Filoviridae and Bornaviridae. 
Members of Mononegavirales are enveloped viruses with negative sense RNA genome. 
Rhabdoviridae also includes other genera such as Lyssavirus, Ephemerovirus, 
Novirhabdovirus, Cytorhabdovirus and Nucleorhabdovirus. VSV has two different 
serotypes, Indiana (VSVI) and New Jersy (VSV NJ). Though certain differences exist, 
both the serotypes exhibit similar properties (Martinez & Wertz, 2005). VSVI is the most 
studied serotype from molecular biology point of view.   
1.3 Structure of the virion 
Mature virion of VSV appears bullet shaped with a rounded tip and flattened 
bottom. VSV is approximately 180 nm long and 80 nm wide. The genomic RNA of VSV 
is 11, 161 nucleotides and lacks the 5‟ cap and 3‟ poly A tail. Recently a three 
dimensional structure of trunk of VSV virion has been determined with the use of cryo 
electron microscopy (Ge et al., 2010).  
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Figure 1.1 Cryo-electron microscopic architecture of virion of VSV (From Ge et al., 
2010, Science) 
N molecules are represented in green whereas M proteins are shown in blue. The inner 
and outer leaflets of the envelope are represented in purple and pink.  
  
5 
 
The outer most layer is a lipid envelope decorated with the glycoprotein (G). The lipid 
envelope is derived from the host cell plasma membrane from which the virus buds and is 
composed of phospholipids and cholesterol. The middle layer consists of the matrix (M) 
protein forming a bridge between envelope and genome.  The innermost layer is the core 
of the virion that contains the virus genomic RNA tightly wrapped with the nucleocapsid 
protein (N). This N-RNA also known as the nucleocapsid or ribonucleoprotein core to 
which the viral RdRp, a complex of the large polymerase protein (L) and the 
phosphoprotein (P) associate. The interaction of N subunits together with the M and 
nucleocapsid interaction imparts the classic bullet shape to the virion.  
1.4. Viral genome organization  
VSV contains a non-segmented negative-strand RNA genome. Because of the 
negative-sense nature, the viral genome does not function as an mRNA to synthesize 
proteins. The extreme 3‟ end contains a non-coding leader RNA gene of 47 nt while the 
5‟ end contains the complement of the non-coding trailer sequences of 59 nt. The leader 
and trailer regions contain sequences essential for transcription, replication and virus 
assembly. The protein-coding genes are organized in a modular fashion in the order 3‟-N-
P-M-G-L-5‟. Each gene is flanked by sequences important for generation of capped and 
polyadenylated mRNAs. The untranslated regions of mRNAs do not contain sequences 
required for translational control or mRNA turnover. Translation of viral mRNA is 
dependent on host cell translational machinery.  
1.5 Viral genome products 
1.5.1 Nucleocapsid protein 
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The nucleocapsid (N) protein is 422 aminoacids long and is a basic protein with a 
net positive charge. VSV genome inside the virion as well as in the infected cells is 
always wrapped by the nucleocapsid (N) protein. Approximately 1200 copies of N 
molecule cover the entire genome with each N molecule covering 9 nucleotides (Green et 
al., 2006) and this Encapsidation is important for its biological activity. N protein when 
expressed alone, can encapsidate cellular RNA, but when expressed along with P protein 
becomes competent to bind viral RNA (Masters & Banerjee, 1988a).  Chemical probing 
analysis suggest that the N proteins sequester the phosphodiester backbone whereas the 
bases are exposed for the polymerase to recognize them for transcription and replication 
(Iseni et al., 2000). Crystal structure of N protein bound to the RNA revealed that N 
protein consists of two separate lobes and the RNA is sequestered inside the grove 
generated by these two lobes (Green et al., 2006). Each monomer of N protein also 
interacts with three adjacent N protein monomers and this interaction help stabilize N-
RNA decameric disc like structure found in cells expressing the N protein as well as 
those in virus-infected cells. Recent evidences also favor a model where N protein 
reversibly encapsidates and releases the RNA and thus allows the polymerase to gain 
access for transcription and replication  (Green & Luo, 2009). N protein is present in the 
replicase complex but is not present in transcriptase complex (Qanungo et al., 2004) 
suggesting differential role for N protein in modulating virus RNA synthesis. Recently 
we and others have identified a role of N protein in the regulation of transcription and 
replication of the N-RNA template (Harouaka & Wertz, 2009; Nayak et al., 2009).  
1.5.2 Phosphoprotein 
7 
 
Phospho (P) protein is 265 amino acids long and is post translationally modified. 
The P protein is found with different degrees of phosphorylation in infected cells and in 
the virions (Barik & Banerjee, 1992; Chen et al., 1997). Although early mutagenesis 
studies have identified domains in the P protein, based on the recent structural and 
functional studies, we proposed a new domain-organization of this protein. The central 
region of the molecule (P central domain or PCD, spanning residues 107-177) containing 
parts of the hinge region folds independently and is involved in oligomerization of the 
protein (Ding et al., 2006). The crystal structure PCD predicts that an α-helix and two β-
hairpins in this domain are critical for homodimer formation and that the N and L binding 
domains likely reside outside of this central domain. The C-terminal domain of P (PCTD, 
spanning residues 183-265) also folds as an autonomously folding unit, whose structure 
has been recently solved alone (Ribeiro et al., 2008) or in complex with the N protein 
(Green & Luo, 2009). Indeed, the structure of PCTD in complex with N protein confirms 
that PCTD interacts with N protein. For viral RNA synthesis to ensue, the P protein must 
interact with N and L proteins. The structure of the N-terminal domain (PNTD spanning 
residues 1-106) of the protein is not known at this time; it is presumed to fold 
independently and likely encode critical determinants of P protein functions like 
transcription activity and L protein binding activity. This domain also has been shown to 
interact with and maintain the N protein in an encapsidation-competent form (Chen et al., 
2007).  
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Figure 1.2. Genome organization of VSV 
Schematic representation of VSV genome is shown. 3‟ end contains leader and 5‟ end 
contains trailer. Corresponding  positions of genes also shown.  
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The P protein forms a complex with N protein known as N
0
-P complex and this is 
competent to bind viral RNA (Masters & Banerjee, 1988a). The binding of N
0
-P complex 
to the RNA also involves interaction of P protein with the L protein. Recognition of RNA 
by the L protein is mediated through the P protein (Emerson & Yu, 1975). Thus, P 
protein plays a crucial role in RNA recognition by the L protein. P protein also 
participates with the L protein in different ratio to form transcriptase and replicase 
complex (Qanungo et al., 2004). Recently the structure of VSV nucleocapsid in 
association with the P protein has been solved (Green & Luo, 2009). It was suggested 
that N protein and P protein undergo conformational change upon interaction with the 
RNA to accommodate the L protein for transcription and replication.   
1.5.3 Matrix protein 
The matrix (M) protein is synthesized in the infected cell as a soluble protein and 
also is the most abundant protein in the mature virion (1600 copies). M protein consists 
of 229 amino acids and the amino terminal region constitute signal for membrane binding 
(Lenard & Vanderoef, 1990). It  plays a critical role in virus assembly by binding with 
the nucleocapsids (Chong & Rose, 1994). The classic bullet shaped structure of VSV was 
due to interaction of M with the nucleocapsids. VSV budding occurs at the plasma 
membrane and M protein forms membrane microdomains at the plasma membrane where 
there is co-localization of nucleocapsids and the M protein (McCreedy & Lyles, 1989; 
Ohno & Ohtake, 1987; Swinteck & Lyles, 2008).  Nucleocapsids are selectively recruited 
by the M protein for assembly (Flood & Lyles, 1999). VSV M protein contains a late 
domain (PPPY), which appears to be responsible for recruiting the host cellular 
machinery for final release of virus particles (Harty et al., 2001; Jayakar et al., 2000). In 
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addition to its role in virus assembly and budding, M protein also plays a role in virus 
pathogenesis by inhibiting interferon synthesis and inducing apoptosis (Ahmed et al., 
2003; Kopecky & Lyles, 2003a). Several lines of evidence also indicate that M protein 
mediated cytopathic effect is due to the suppression of host gene function (Ahmed & 
Lyles, 1998; Ferran & Lucas-Lenard, 1997; Jayakar & Whitt, 2002). By interacting with 
Rae1, M protein inhibits nucleocytoplsmic transport of host genes (Enninga et al., 2002; 
Faria et al., 2005). Cytopathogenesis by M protein is also due to inhibition of host 
translation (Connor & Lyles, 2002). Induction of apoptosis in VSV infection is due to M 
protein alone (Kopecky & Lyles, 2003b; Kopecky et al., 2001). VSV-M protein mediated 
apoptosis is due to induction of intrinsic apoptotic pathway (Balachandran et al., 2000; 
Kopecky et al., 2001).  
1.5.4 Glycoprotein 
Glyco protein (G) is the only protein present in the outer envelope of the virion. G 
protein is a type I transmembrane protein. On the surface of the virion, G proteins exist in 
the form of trimers. Majority of the G protein is located outside the virion and constitute 
the ecto domain. The crystal structure of G protein has been solved recently (Roche et al., 
2006; Roche et al., 2007). VSV can infect almost all the cell types and G protein- 
mediated attachment to the receptor is a critical determinant for this. VSV G  has affinity 
for negatively charged phospholipid  protein  and this is important for attachment and 
membrane fusion (Carneiro et al., 2002). Low pH-dependent conformational change of 
the G protein and fusion inside the endosome is necessary to release the virion content 
(Puri et al., 1988). The cytoplasmic amino acid sequences are required for incorporation 
of G protein into the virion  (Whitt et al., 1989). G proteins form specialized membrane 
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micro domains on the plasma membrane for virus budding and these are formed 
independent of other viral proteins (Brown & Lyles, 2003). Recent evidence suggest that 
G protein participate with M protein in virus budding (Swinteck & Lyles, 2008).   
1.5.5 Large polymerase protein 
Large polymerase protein (L) is the catalytic subunit of viral polymerase and is 
required for transcription and replication. In addition to RNA synthesis, L protein also 
catalyzes mRNA cap addition and cap methylation (Ogino & Banerjee, 2007; Sleat & 
Banerjee, 1993). The L protein is a 250 kDa protein and composed of six conserved 
region (Poch et al., 1990). The RNA polymerase activity maps to conserved region III 
(Sleat & Banerjee, 1993), whereas the mRNA capping and cap methyl transferase 
activities maps to region V and region VI respectively (Li et al., 2005; Li et al., 2008). 
Electron microscopy and deletion analysis  showing the molecular architecture of L 
protein provided more detail understanding of the organization of different functional 
domains of the L protein (Rahmeh et al.,2010).  L protein is also a component of both 
replicase and transcriptase (Qanungo et al., 2004).  
1.6 VSV life cycle 
VSV is an arthropod-borne virus. VSV infection in the arthropod remains 
asymptomatic where as in the animals the virus causes disease. The lifecycle of VSV is 
typical representative of most non-segmented negative strand RNA viruses. Infection 
starts with entry of virus to susceptible cells and it involves several stages.  
1.6.1 Virus attachment  
VSV can infect almost all cell lines in culture condition but the exact receptor for 
VSV has not been identified. However because of wide tissue tropism, the receptor for 
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VSV has been suggested to be a ubiquitous molecule. Phosphatidyl serine, a negatively 
charged membrane phospholipid has been suggested to be the receptor for VSV (Schlegel 
et al., 1983). However others have provided evidence that phosphatidylserine is not the 
receptor for VSV (Coil & Miller, 2004). Phosphatidyl serine exists on the inner side of 
plasma membrane and may not be a suitable receptor for VSV attachment. Experimental 
evidence also suggests that endoplasmic reticulum chaperone Gp96 is a factor required 
for VSV G-mediated attachment of virion to the host cell surface (Bloor et al.,2010).  
Non- specific electrostatic  and hydrophobic interaction between VSV and host cell may 
mediate attachment of virion to the cell surface (Bailey et al., 1984).  Also the pH- 
dependent conformation of G protein of VSV is required for attachment of virus to cell 
membrane (Fredericksen & Whitt, 1998).  
1.6.2 Virus entry and uncoating 
After attachment, virus enters to the cell by receptor mediated endocytosis. VSV 
was one of the model system used to investigate the mechanism of virus entry as early as 
1980s (Matlin et al., 1982). In fact, VSV entry was shown to be dependent on clathrin 
mediated endocytosis (Cureton et al., 2009; Cureton et al., 2010; Sun et al., 2005). Once 
attached, virions are internalized by clathrin-coated vesicles.  
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Figure 1.3:  Schematic representation of VSV life cycle   
Model of VSV infection cycle showing important stages starting fromvirus adsorption to 
virus budding. (Adapted from The Rhabdoviruses, R.R. Wagner Ed., Plenum Press, New 
York) 
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These coated vesicles after losing their coat form early endosomes. From which, virus is 
presented to the multi vesicular bodies. As virus travels through the endocytic pathways, 
the pH of the carrier vesicles progressively drops and there is a pH-dependent 
conformational change of the G protein of VSV. At pH below 6.5, G protein fuse with 
the endosomal membrane and the internal contents of the virus is trapped in the 
endosome. A back fusion event in the multivesicular body is necessary for release of viral 
RNA to the cytoplasm (Le Blanc et al., 2005).  Using a dual fluorescent VSV, we have 
also demonstrated that it takes approximately 28 minutes for the virus to deliver its 
content to the cytoplasm after attachment to the cell surface (Das et al., 2009).  
1.6.3 Transcription of Genome 
Dissociation of M protein from the input nucleocapsid is the primary event of 
uncoating and is necessary for transcription of the viral genome (Li et al., 1989; Rigaut et 
al., 1991). VSV genome is always associated with the N protein. The viral RNA 
dependent RNA polymerase (RdRp) which is a combination of the L protein and P 
proteins is also associated with the N-RNA template for transcription and replication.  
VSV contains a negative strand RNA genome and cannot initiate protein synthesis 
directly. Therefore VSV packages its own RdRp to initiate RNA synthesis. Primary 
transcription from the input RNA is the first biosynthetic step after infection. Viral 
polymerase directs the synthesis of viral mRNA without the help of viral proteins 
(Baltimore et al., 1970; Emerson & Yu, 1975; Moyer & Banerjee, 1975). A general 
feature of VSV as well as other non-segmented negative strand RNA viruses is the 
sequential nature of transcription (Abraham & Banerjee, 1976; Ball & White, 1976). As a 
result of sequential nature of viral genome transcription and attenuation of transcription at 
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each gene junction, a gradient of mRNA abundance is seen in infected cells as well as 
under in vitro transcription reactions. The genes present at the 3‟ promoter proximal end 
are transcribed more frequently compared to the genes present in the 5‟ promoter distal 
end (Villarreal et al., 1976).   
The common features in all NNS RNA viruses is that transcription is sequential  
(Abraham & Banerjee, 1976) and that the genes located at the 3‟-end of the genome are 
transcribed more frequently than the genes present at the 5‟-end, resulting in a gradient in 
mRNA abundance (Iverson & Rose, 1981). Although several models, such as precursor-
cleavage model, multiple entry site model, were proposed to account for the polar and 
sequential nature of transcription of VSV genomes, the most favored model (Emerson, 
1982) posits that the RdRp begins transcription from the extreme 3‟-end of the genome to 
generate Le RNA and then stops and reinitiates transcription at the N gene start site. In 
this single-entry, stop-start model, as the RdRp moves along the template, it stops and 
starts at various gene junctions, generating the individual mRNAs. Transcriptional 
attenuation at the gene junctions due to the inability of a fraction of the RdRp to reinitiate 
transcription could result in the gradient in mRNA abundance. As the N protein becomes 
available, its association with the nascent Le RNA allows the RdRp to read-through the 
Le-N and other gene junction sequences, generating the N protein-encapsidated full-
length replication products. How the N protein binding to Le sequences allows the 
polymerase to readthrough the gene junction remains an open question. Although the 
model accommodates many of the available data, more recent data are incompatible with 
this single-entry model. If one considers single-entry for the RdRp at the 3‟-end of the 
genome, Le RNA should be synthesized in excess over the N mRNA because 
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transcription is sequential and polar. However, polR1 mutants of VSV synthesize excess 
N mRNA over Le RNA suggesting that the RdRp initiates transcription from the N 
mRNA start site independent of Le RNA synthesis (Chuang & Perrault, 1997). The 
results implicate the presence of two entry sites for the RdRp, one at the extreme 3‟-end 
and the other at the Le-N junction, although they do not rule out the possibility of RdRp 
entering only at the 3‟-end and reaching the N mRNA start site at the Le-N junction by a 
nontranscriptive scanning mode. The demonstration that transcription and replication 
initiate at separate sites in VSV  (Whelan & Wertz, 2002) and the purification and 
characterization of two distinct RdRp complexes from VSV-infected cells performing 
transcription and replication functions separately (Qanungo et al., 2004) also implicate 
the two-entry site model.  
The leader and trailer sequences not only play roles in encapsidation and 
packaging of the genome into nascent virion, but also play indispensable role in the 
regulation of transcription and replication (Li & Pattnaik, 1999; Whelan & Wertz, 
1999b). Deletion analysis in the leader region identified that first 24 nucleotides are 
responsible for replication and transcription whereas nucleotides 25 to 47 are required for 
transcription (Li & Pattnaik, 1999). The leader and N gene junction sequences also play 
important role in transcription (Whelan & Wertz, 1999b). Using a bipartite VSV replicon 
system, the role of conserved gene junction sequences has also been demonstrated 
(Stillman & Whitt, 1997; 1998). First three residues in the mRNA, “UUG” are important 
not only for transcription but also for mRNA capping and polyadenylation (Stillman & 
Whitt, 1999). Alteration of these signals affects VSV polymerase processivity, and results 
in premature transcripts.  Large polymerse protein also has additional functions of 
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capping and methylation of the nascent messages.  Capping of the nascent transcripts is 
important for transcription elongation and failure of correct 5‟ capping results in abortive 
transcription (Stillman & Whitt, 1999). VSV polymerase-mediated capping is different 
from that of host (Ogino & Banerjee, 2007). All the VSV mRNAs have conserved 
sequences 5‟ AACAG 3‟. VSV polymerase adds the cap to the mRNAs but not to the 
leader sequence. The histidine-arginine motif in the L protein is responsible for transfer 
of 5‟ monophosphorylated RNA onto the GDP to form the cap structure. Highly 
conserved sequences present at the end of the each protein-coding gene also regulate 
transcription termination and polyadenylation. Conserved sequences at the intergenic 
region (3‟ AUAC UUUUUUU -G/C A- UUGUC nn UAG, n is not conserved) also 
regulate transcription. Mutagenesis studies have identified a critical role of these 
sequences in transcription termination as well as efficient transcription re-initiation of 
each gene (Barr et al., 1997a; b; Hwang et al., 1998). Transcription initiation requires 
efficient termination of preceding gene (Stillman & Whitt, 1997; 1998). The mechanism 
by which the AUACUUUUUUU sequence regulates polyadenylation is not completely 
understood. It has been proposed that viral polymerase adds the polyadenylate residues to 
the mRNAs by reiterative transcription. The intergenic di nucleotides G/CA act as a 
spacer for transcription termination and re-initiation. The relative distance between the 
gene start and gene end also plays  a role in transcription termination (Whelan et al., 
2000).  
1.6.4 Replication of Genome 
During replication, full-length viral genome is replicated to produce anti-genome.  
The anti-genome subsequently serves as a template to produce full-length genome. The 
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fundamental difference between replication and transcription is the requirement of newly 
synthesized viral proteins for replication. In the presence of cycloheximide, replication is 
inhibited whereas transcription still continues  (Wertz & Levine, 1973).  In a cell free 
system, N protein was found to be required to encapsidate the genome for replication 
(Patton et al., 1984) . P protein along with N protein is required for replication of genome 
in infected cells (Peluso, 1988).  It has been also suggested that the P protein maintains 
the N protein in a soluble encapsidation competent form (Masters & Banerjee, 1988a; b). 
Both the genome and anti-genome contains signal at their 3‟end for replication.  The 
genome also contains signal for packaging into progeny virion. Studies using 
minigenome and defective interfering particles have been instrumental in mapping the 
sequences required for efficient replication (Li & Pattnaik, 1997; 1999). The 3‟ termini of 
genome and anti-genome are identical at 15 of 18 position and these  terminal 
complementarities were found to be essential for genome replication (Wertz et al., 1994). 
However the sequences differ significantly at positions 19-46. In the genomic promoter, 
these sequences are required for transcription whereas in the anti-genomic promoter these 
sequences are required for replication (Li & Pattnaik, 1997; 1999). Because the anti-
genomic promoter replication is more efficient than the genomic promoter replication, 
virus infected cells more genomic copies are found than the anti-genomic copies. 
Recently, separate VSV transcriptase and replicase carrying transcription and replication 
functions respectively has been identified (Qanungo et al., 2004). The replicase is a 
complex of L, N and P proteins whereas transcriptase consists of L and P protein along 
with host guanylyltransferase, translation elongation factor 1α and heat shock protein 60. 
The precise role of these cellular proteins in genome transcription is unknown.  Although 
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there is considerable advancement of the research in identifying the cis-and trans-acting 
viral elements in genome replication and transcription, little is known about the role of 
host proteins modulating transcription and replication.  
1.6.5 Virus assembly 
VSV assembly occurs at the plasma membrane. Individual viral components are 
transported to the site of assembly through different routes. The G protein is transported 
to the plasma membrane through the secretory route and forms microdomains (Brown & 
Lyles, 2003). The sequence of G protein facilitating budding was shown to be at the 
membrane proximal region as well as at the cytoplasmic domain (Robison & Whitt, 
2000; Schnell et al., 1998). Viral M protein is synthesized as a soluble protein and is 
transported to the plasma membrane by a yet unknown mechanism and form separate 
microdomain independent of G protein (Swinteck & Lyles, 2008). The amino terminal 20 
amino acids of M protein is required for membrane association (Lenard & Vanderoef, 
1990). Nucleocapsids once synthesized in the cytoplasm are transported to the 
plasmamembrane in microtubule dependent manner (Das et al., 2006). The nucleocapsids 
are selected to bind with the M protein for budding because majority of intracellular 
nucleocapsids do not interact with M protein (Flood & Lyles, 1999). VSV genome 
contains a cis-acting signal at the 5‟ end of the genome which is required for efficient 
assembly into progeny virion (Whelan & Wertz, 1999a). However the exact mechanism 
by which the nucleocapsids are selected for assembly is not known. Following assembly, 
virus budding occurs. M protein recruits cellular proteins at the site of budding for final 
release of virus particles (Harty et al., 1999). Proline rich sequence in the M protein has 
been identified to be responsible for budding (Irie et al., 2004a). Ubiquitination of M 
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protein was shown to be required for final release of virions (Jayakar et al., 2000). 
Cellular proteins involved in membrane trafficking such as TSG101 or VPS4 have been 
implicated in budding of HIV, but are not required for budding of VSV (Irie et al., 
2004b).  
1.7 Defective interfering particles of VSV 
Defective interfering particles (DI particles) are sub-genomic virus particles 
generated by large deletion of virus genome during the process of replication (Schubert et 
al., 1979). Because DI particles do not encode for any protein, replication of their 
genome depends on the wild-type virus to provide the replication proteins. Several 
classes of defective interfering particles for VSV have been well characterized (Meier et 
al., 1984; Perrault & Leavitt, 1978a; b).  Because the DI particle genomes are shorter and 
they contain a stronger promoter for replication, they inhibit the replication of wild type 
virus (Pattnaik et al., 1995; Perrault & Holland, 1972).  In laboratory conditions, DI 
particles can be generated by a high multiplicity of infection of wild type virus. The sizes 
of these DI particles are also small; therefore, they can be easily separated from the wild 
type virus by density-gradient centrifugation. Because of the above unique properties, 
during the 1970s and 1980s, DI particles provided an excellent tool to study the process 
of virus replication and much of our understanding of VSV replication comes from 
studies with DI particles.  
1.8 Reverse genetics system of VSV 
Genetically engineered non segmented negative strand RNA viruses offer a 
unique tool to investigate several aspect of virus biology.  For positive strand RNA 
viruses, recovery of infectious virus from the cDNA was established in the early 1980s 
21 
 
(Racaniello & Baltimore, 1981).  However for negative strand viruses, because of the 
typical replication cycle of these viruses, development of reverse genetics system faced 
several hurdles. The first system to recover an infectious viral genome was established 
with VSV DI particles (Pattnaik et al., 1992). In this system, cDNA clones expressing N, 
P, L, M and G proteins were transfected along with cDNA clone of DI genome. The 
cDNAs were under the control of bacteriophage T7 promoter. Thus the expression of the 
viral proteins and the DI RNA was carried out by the bacteriophage T7 RNA polymerase,  
which was provided by infecting the cells with a recombinant vaccinia virus expressing 
the T7 RNA polymerase (Pattnaik et al., 1992).  Use of a hepatitis delta virus ribozyme to 
generate authentic 3‟ end was required for replication of the viral genome (Pattnaik et al., 
1992). Subsequently infectious full length rabies and VSV were generated following the 
above system (Lawson et al., 1995; Schnell et al., 1994). Negative strand RNA viruses 
from other families such as paramyxovirus, Bornavirus, Ebolavirus were also recovered 
entirely from cloned DNA using similar approach (Radecke et al., 1995; Schneider et al., 
2005; Volchkov et al., 2001). With the advent of reverse genetics system, it has been 
possible to engineer changes in viral genomes as well as to sub-genomic replicons to 
probe the role and requirement of cis-acting signals in viral genome  replication and 
transcription (Conzelmann, 1998).     
1.9 Host factors required for VSV infection 
Viruses are obligate intracellular parasites. Viruses such as VSV encode for 
limited number of proteins and the functions of those proteins are limited to replicate the 
genomes. Many steps in the life cycle of VSV such as attachment, entry and uncoating, 
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genome replication and assembly depend on specific host cell functions. Virus and host 
interaction is also complex. Host has developed strategies to eliminate the invading  
viral pathogen, whereas viruses have developed strategies to counter the host defense 
systems. Viruses have also historically been used to discover and characterize several 
cellular mechanisms such as DNA replication, membrane fusion, RNA capping, internal 
ribosomal entry during translation etc. Comprehensive knowledge about such 
critical players in virus lifecycle will provide a valuable understanding about molecular 
mechanism of virus infection. Such understanding will also facilitate generation of novel 
drugs that target an essential host protein involved in virus replication and will help to 
avoid selection of drug-resistant mutant viruses. Until recently global analysis of host 
proteins required for virus infection was hindered by non-existent of suitable system. 
With the advancements in genomics and knowledge of RNA interference mechanisms, it 
has been possible to develop genome-scale loss-of-function screens to identify host 
factors that influence virus infection.  In the past, VSV has led the pathway to understand 
molecular aspect of virus genome replication and transcription as well as immune 
recognition. However little is known about the host factors involved not only in VSV but 
also in other negative strand RNA viruse infections.  
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Figure 1.4:   Schematics of reverse genetics system of VSV 
BHK-21 cells are infected with recombinant vaccinia virus expressing T7 RNA 
polymerase. Subsequently these cells are transfected with full length cDNA clone of 
VSV and support plasmid expressing viral N, P and L proteins. At 48 hrs post 
transfection, supernatant is collected and passaged onto naive BHK-21 cells. Recovery of 
virus is evidenced by cytopathic effects and immunofluorescent staining for viral M 
protein. Also, using this system replication of DI genome can be examined when DI 
particles are infected to cells expressing viral N, P and L proteins.   
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 Recently, elegant studies by Gruenberg and colleagues demonstrated that 
uncoating and delivery of VSV genome occur by a back fusion event inside the 
multivesicular endosomes and host proteins Alix and TSG101 are required for this event 
(Le Blanc et al., 2005; Luyet et al., 2008). VSV transcriptase contains cellular guanylyl 
transferase, heat shock protein 60 and eukaryotic elongation factor 1-alpha along with 
viral  N, P and L protein (Qanungo et al., 2004).  The exact role of these host factors in 
viral replication and transcription is not known. Involvement of other cellular factors in 
VSV replication is also not known at this time. VSV matrix protein contains late domain 
and utilizes host cell factors such as Nedd4 like ubiquitin ligase (Harty et al., 1999) for 
the release of the assembled virus. In contrast to HIV and Ebola virus, VSV budding does 
not require activity of ESCRT III complex (Irie et al., 2004b).  Involvement of other 
proteins in the budding of VSV is not known.  
 A limited number of restriction factors are also known to modulate VSV and 
other negative strand RNA virus infection. Innate immune system is the first line of 
defense against the invading pathogen. In an in vitro system, using VSV and Rabies 
RNA, cytoplasmic pattern recognition receptor for RNA such as Retinoic acid inducible 
gene I (RIG-I) was identified (Hornung et al., 2006; Pichlmair et al., 2006). Recognition 
of RNA by the cytoplasmic sensors leads to induction of interferon signaling pathways. 
Subsequent studies have identified the ligand for the RIG-I as base paired RNA with 5‟ 
triphosphate (Schlee et al., 2009; Schmidt et al., 2009).  RNAi interference was also 
recently identified as an evolutionarily conserved antiviral mechanism in insects, plants 
and animals (Ding & Voinnet, 2007). VSVwas instrumental as a model pathogen to 
decipher the antiviral mechanism mediated by RNA interference in C. elegans (Wilkins 
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et al., 2005) Drosophila   (Sabin et al., 2009) and mammals (Otsuka et al., 2007). The 
above studies have identified several key elements in the RNAi pathway acting as host 
resistant factors for VSV. Nevertheless the molecular mechanism by which VSV subverts 
these antiviral defense pathways is poorly understood.    
1.10 Sub-genomic replicon system to study viral replication 
Understanding the virus-host interaction and identifying host proteins involved in 
virus replication pose a major challenge in the field of virology.  Sub-genomic replicon 
bearing cell lines harboring a drug resistant marker for several positive strand RNA 
viruses have been instrumental to study different aspects of virus biology such as viral 
genome replication, identification of host cell factors in virus replication, innate immune 
regulation and identification of drug candidates. Genomes of positive strand RNA viruses 
are infectious and thus it has been possible to establish sub-genomic replicon system by 
deleting structural gene and replacing a drug resistance gene. Cell lines continuously 
supporting replication of such replicons have been reported for several positive strand 
RNA viruses such as Bovine viral diarrhoea virus (BVDV), hepatitis C virus (HCV), 
dengue virus, west nile virus (WNV) and sub acute respiratory syndrome corona virus  
(Behrens et al., 1998; Ge et al., 2008; Lohmann et al., 1999; Ng et al., 2007; Rossi et al., 
2005). Similar to establishment of reverse genetics system for negative-strand RNA 
viruses, development of replicon system for negative- strand RNA viruses is difficult 
because the RNA genome itself is not infectious and the replication and transcription of 
genome requires assembly into a functional nucleocapsid complex. Consequently, 
research in negative strand RNA viruses is lagging behind.   
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1.11 High-throughput siRNA screen to identify host factors required for virus  
infection 
RNA interference was recently identified as a mechanism of post transcriptional 
gene silencing where the RNAi machinery knocks down the endogenous or exogenous 
RNA in a sequence dependent manner (Fire, 1999; Fire et al., 1998) . Completion of 
human genome sequencing project has provided new impetus to the field of genomics 
(Lander, 2011). Coupling RNAi with knowledge of human genome, researchers have 
developed tools to silence gene functions. Also, advances in bioinformatics analysis and 
high-throughput cell- based screening and imaging platforms have made it feasible to 
probe the impact of each and every human gene not only in viral system, but also in other 
pathophysiological conditions (Mohr et al.,2011). RNAi experiments offer loss-of -
function studies. For example, if a particular gene is involved in a virus life cycle, RNAi 
knockdown of that gene gives an altered phenotype after virus infection. In the last five 
years genome-wide siRNA screens using mammalian cell-based systems have led to 
several exciting discoveries in many biological conditions previously seemed impossible 
(Mohr et al.,2011). First genome-wide RNAi screen to identify human host factors 
involved in a virus infection was reported for HIV (Brass et al., 2008). Subsequently 
genome wide RNAi screen has been reported for several other viral systems such as 
influenza (Brass et al., 2009; Karlas et al.,2010; Konig et al.,2010), West Nile virus 
(Krishnan et al., 2008), HCV (Li et al., 2009; Tai et al., 2009). However, before the 
arrival of human genome-wide siRNA screens, drosophila siRNA screen provided 
researchers the opportunity to expand the knowledge of virus-host interaction. Drosophila 
RNAi is robust because there is no interferon system which provided simplicity for data 
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analysis and in addition knockdown of genes is efficient. Most of the Drosophila genes 
have their human orthologs and thus data obtained from Drosophila screens can be 
extended to human system. Easy genetic manipulation to generate knockout flies in short 
period of time offer a unique advantage to study Drosophila as a model organism.  
Studies have been published using Drosophila screen, identifying host proteins involved 
in virus infection as early as 2004 (Cherry et al., 2005; Cherry & Perrimon, 2004).   
 Though the RNAi technology has helped the researchers to achieve critical 
milestones, the field of RNAi is still in its infancy. Multiple groups have completed 
RNAi screen in the same biological system. Ironically the results are dissimilar from 
screen to screen (Bushman et al., 2009; Goff, 2008). Several factors such as types of 
reagents used, type of cell line, assay, degree of depletion of gene and statistical analysis 
could contribute to the disparate results. Recently, there has been an increasing effort to 
identify the reproducibility between the genomic screens and to better  understand the 
RNAi technology (Barrows et al.,2010).  In a high-throughput screen, there are off target 
effects resulting in false positives. Many bioinformatics tools are available to design 
effective RNAi reagents, yet the available reagents are not 100% effective in knocking 
down the targets (Tilesi et al., 2009). Statistical analysis is also one important component 
of a high-throughput screen and the type of analysis used could greatly influence the 
results (Barrows et al., 2010; Birmingham et al., 2009). A new trend of coupling other 
“omics” technologies such as protein-protein interaction map and mRNA microarray with  
the RNAi is also emerging (Mohr et al., 2011).  Nevertheless, researchers could harness 
the power and utility of RNAi technology for several landmark discoveries in wide 
variety of fields in the past several years. Though much of our current knowledge on the 
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biological system exists at the gene level, emergence of new technologies as well as 
refinement of existing technologies of integrative screening and data analysis will 
provide new dimension to the research field. Additional genome-scale data collection will 
shift the paradigm towards a system level understanding rather than at gene level 
understanding.  
1.12 Overall objective and experimental plan 
Identification of host genes affecting virus replication will be valuable to 
understand virus biology and virus-host interaction. Negative- strand RNA viruses 
include several human and animal pathogens. Many of these viruses cause significant 
cytopathic effects in cultured cells after infection. For some of these viruses, specific 
containment facility is required to study the virus biology. Development of a system 
which supports replication of sub genomic replicon will be a major impetus for studies on 
virus-host interactions and drug discoveries and thus the need for specific containment 
can be alleviated. The overall objective of this study was to establish a replicon system 
for VSV as well as to identify host factors required for VSV infection in cell culture 
system.  
1.12.1 Objective 1: Hypothesis and experimental approach 
Development of replicon systems for positive strand RNA viruses has greatly 
contributed to our understanding of virus biology.  Development of such replicon system 
poses a major challenge for negative-strand RNA viruses because the RNA of negative- 
strand RNA viruses exist as nucleocapsids bound to viral proteins and must be 
transcribed to produce proteins for replication.  Availability of such a replicon system for 
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VSV will help to facilitate a detail understanding of complex nature of virus-host 
interaction as well as rapid drug discovery.  
 Since VSV genome replication depends on presence of the replication proteins 
such as N, P and L, it was hypothesized that cells constitutively expressing replication 
proteins of VSV can be used to replicate a minimal replicon of VSV encoding a drug 
resistant marker or defective interfering particle genome of VSV. Also a modified sub 
genomic replicon of VSV lacking M and G proteins can be replicated in the cells and if 
positive selection is applied a cell line can be developed harboring the replicon. Based on 
these hypotheses, the objective was to establish a cell line supporting continuous 
replication of a sub-genomic replicon of VSV. To achieve this objective, two different 
approaches were used. In the first approach, a cell line which constitutively expresses 
VSV replication proteins was generated.  Long term replication of DI genome was 
attempted to establish in this helper cell line.  In the second approach, sub-genomic 
replicon of VSV where M and G protein coding regions were deleted from the full length 
cDNA was used to generate a cell line. This sub-genomic replicon also encoded a drug 
resistance marker [neomycin phosphotransferase gene (Neo
r
)] under VSV specific 
promoter. For initial round of replication, proteins expressed from the helper plasmids are 
required. It was expected that subsequent rounds of replication will then become 
independent of the proteins provided through the helper plasmid as this replicon will 
produce the proteins necessary to sustain its own replication. Cells were expected to 
confer resistance to the drug G418 when there is replication dependent expression of 
Neo
r
.   
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1.12.2 Objective 2: Hypothesis and experimental approach 
 During the course of infection, viruses exploit the sub cellular milieu and 
orchestrate several key events in order to replicate and propagate. Host cells provide the 
building blocks for viral metabolism as well as in some cases serve as platform for 
genome replication.  Viruses usurp several cellular pathways to complete each step of 
their life cycle. Identification of these host cell functions has been a long standing interest 
in virology. So far there has not been significant effort to identify host factors required 
for VSV or any other non-segmented negative strand RNA viruses. To fill the gap in the 
knowledge, the objective was to identify the host proteins involved in VSV infection in 
cell culture condition. To achieve this objective, a genome-wide siRNA screen was 
employed to silence each of the known and putative genes encoded in the human 
genome. A total of 23,000 human genes were knocked down individually, and their effect 
on viral replication was interrogated using a high-throughput cell based assay. A total of 
four separate siRNAs targeting each gene using a format of two different pools, each 
containing two siRNAs was used. The hits generated after the primary screen were 
validated in a secondary screen using different set of siRNAs to minimize the off-target 
effects and false discoveries.  
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Cell culture and maintenance of cell lines 
Baby hamster kidney (BHK-21) cells were obtained from ATCC (CCL-10). 
BHK-21 cells were maintained in minimal essential media (MEM) containing 5% heat- 
inactivated foetal bovine serum (FBS) and supplemented with 100 units of Penicillin, 20 
units of streptomycin and 20 units of kanamycin (1X PKS) per one ml of media. HeLa 
cells (ATCC: CCL2) and Human embryonic kidney (HEK 293), HEK-293T cells were 
maintained in Dulbecco Modified Eagle‟s media with 10% heat-inactivated FBS and 1X 
PKS. Madin Darby canine kidney (MDCK) and Vero cells were obtained from 
Veterinary Diagnostic Center, UNL. BER40 cells were obtained from George Belov 
(University of Maryland).  
2.2 Preparation of stock of VSV 
 Plaque purified single clone of viruses (VSV-eGFP, VSV PeGFP or wild type 
VSV) were grown in BHK-21 cells. Confluent monolayer of BHK-21 cells in 100 mm 
dishes were infected with 0.01 multiplicity of infection in 1 ml of media. After 1 hr of 
adsorption, unbound viruses were removed by washing with DMEM and fresh DMEM 
ith 2% FBS and 1X PKS was added. After 16-18 hr post infection, supernatant was 
collected, clarified by centrifugation and stored in -80
o
C in small aliquots. The titers of 
these viruses were determined by plaque assay using BHK-21, HeLa and HEK-293 cells.  
2.3 Preparation of stock of LCMV and HPIV3 
GFP expressing LCMVr3-GFP (Emonet et al., 2009) was grown in BHK-21 cells. 
Fluorescent focus forming unit was calculated after infecting HeLa cells. GFP expressing 
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HPIV3-GFP (Zhang et al., 2005) was grown in HeLa cells. Fluorescent focus forming 
unit was calculated after infecting HeLa cells with HPIV3-GFP.   
2.4 Preparation of recombinant vaccinia virus (vTF7-3) stock 
Stock of a recombinant vaccinia virus expressing bacteriophage T-7 polymerase 
(Fuerst et al., 1986) was generated in BHK-21 cells using a protocol as described 
previously (Pattnaik & Wertz, 1990). The titer of the stock vTF7-3 was determined by 
plaque assay in BHK-21 cells.  
2.5 Stocks of defective interfering particles  
Defective interfering particles (DI) particles used in these studies were DI-T 
particles with a panhandle type genome (Meier et al., 1984; Pattnaik & Wertz, 1990). 
Stocks of these DI particles were generated as described earlier (Pattnaik & Wertz, 1990).  
2.6 Plaque assay 
Plaque assay for VSV was conducted in BHK-21 and HeLa cells. A 10-fold serial 
dilution of the virus stock was prepared in cold DMEM. BHK-21 cells or HeLa cells in 
12-well tissue culture plates were infected with 100μl of the diluted virus stock as  
inoculum per well. After 1 hour of adsorption, unbound viruses were removed by 
washing two times in DMEM. Equal mixture of 1.2% low melting point agarose and 2X 
DMEM containing 10% FBS and 2X PKS was prepared and added to the monolayer. 
Cells were incubated undisturbed inside the hood for 15 minutes allowing the agar to 
solidify. Cells were further incubated at 37
o
C for 16-20 hours for plaques to develop. 
Subsequently, cells were fixed (2% glutaric dialdehyde in PBS) for 1 hr. Agar plugs were 
removed and fixed plaques were stained with 0.1% crystalviolet in 30% methanol. 
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Numbers of plaques were counted for each dilution and virus titer was determined by 
multiplying the number of plaques with dilution factor.   
2.7 Nucleocapsid preparation and transfection 
VSV-eGFP was grown in BHK-21 cells in four 100 mm tissue culture plates. At 
16 hour post infection, approximately 6 ml of supernatant was obtained per plate. The 
supernatant was clarified at 2000 RPM for 15 min at 4
o
C to remove the debris. 
Approximately 11 ml of supernatant was loaded onto 2 ml of 15% sucrose cushion (15% 
sucrose in NTE) per tube and pelleted by ultracentrifugation for 2 hours at 36,000 rpm 
using a SW41 rotor. The pellet was resuspended in 2 ml of nucleocapsid generation 
buffer (10 mM Tris-HCl pH 8.0, 0.4 M NaCl, 1.85% Triton X, 5% glycerol, 0.6mM 
DTT)  per tube and kept on ice for 2 hrs with intermittent shaking. The nucleocapsids 
from both the tubes were pooled, loaded on a 15% sucrose cushion made with 
nucleocapsid generation buffer and pelleted by centrifugation at 36,000 rpm for 4 hrs. 
The pelleted nucleocapsid was then resuspended in 100 μl resuspension buffer (5% 
glycerol and 10 mM Tris-HCl, pH 8.0), aliquoted and frozen in -80
o
C. Long-term storage 
resulted in approximately 50% loss of activity. Hence, nucleocapsids were used within 
one week after generation.  
 Nucleocapsids were transfected using Lipofectamine 2000 (Invitrogen). To 100 μl 
OptiMEM (Invitrogen) thawed at room temperature, 4 μl of lipofectamine was added and 
the mixture was incubated for 5 minutes. In a separate tube, 4 μl of nucleocapsids were 
added to100 μl of OptiMEM. The diluted nucleocapsid and lipofectamine mixtures were 
combined together and incubated at room temperature for 20 minutes for complex 
formation. HeLa cells grown in one well of a 6-well plate were washed once in DMEM 
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and 600 μl of OptiMEM without antibiotic was added. To this, the nucleocapsid and 
Lipofectamine complexes were added drop wise, mixed gently and incubated for 6 hours. 
Absence of virus particles was examined in the nucleocapsid preparation by adding the 
nucleocapsids without Lipofectamine and monitored for cytopathic effect.  
2.8 Molecular cloning  
2.8.1 Preparation of chemically competent bacteria 
Chemically competent Escherichia coli (E. coli) DH5α was prepared by Inoue 
method (Sambrook & Russell, 2001). Competent bacteria were frozen in small aliquots in 
-80
o
C.  
2.8.2 Recombinant DNA technique 
Restriction endonuclease enzymes were purchased from New England Biolabs 
(Ipswich, MA). Restriction digestions of the plasmids or PCR products were done with 
the restriction endonucleases as per the manufacturer‟s recommendations. Purification of 
the digested fragment from the low melting point agarose gel was done using phenol and 
chloroform method (Sambrook & Russell, 2001). Purified DNA was resuspended in 
water.  DNA ligation was performed by ligating the insert and vector with T4 DNA ligase 
(Invitrogen). Vector and insert ratio was kept 1:3 to 1:5.  Ligation reaction was carried 
out by incubating the mixture at 2-4 hours at room temperature or 16-18 hours at 16
o
C.  
For transformation, 5μl of ligation mix was added to 50 μl of competent DH5α. Mixture 
was incubated for 30 on ice. Bacteria were heat shocked at 42
o
C for 90 seconds followed 
by incubation for 4 min on ice. Subsequently, 950 μl of room temperature LB broth was 
added and further incubated at 37
o
C for 1 hour. Finally bacteria were plated on LB agar 
35 
 
plates containing appropriate antibiotic for selection of transformants containing 
recombint plasmid.  
2.8.3 Plasmid purification 
Plasmids were purified from the bacteria in small scale by alkaline lysis method. 
Individual bacterial colonies were grown for 8 hr or 16 hr in 1.5 ml LB broth containing 
appropriate antibiotic (Ampicillin or Kanamycin or Chloramphenicol). Pelleted bacteria 
was lysed by 300 μl of TENS buffer (10mM Tris-Hcl pH 8.0 1mM EDTA, 0.1M NaOH, 
0.5% SDS). The cell suspension was neutralized by adding 150 μl of sodium acetate, pH 
5.2. Supernatant was collected into a fresh microfuge tube after pelleting the cell debris. 
Plasmid DNA was precipitated by adding 900 μl of 100% ethanol followed by 
centrifugation for 5 minutes. Precipitated plasmid DNA was dried after washing with ice 
cold 70% ethanol. Dried plasmid was resuspended in 50 μl of tris-EDTA buffer 
containing 100 μg/ml of RNaseA. Large-scale plasmid purification was performed by 
gravity flow column purification method using Qiagen‟s column Tip 100 as per 
manufacturer‟s instructions.  
2.9 Construction of plasmids 
2.9.1 Construction of N, P, L plasmids under the CMV promoter 
pGEM-P, pGEM-N and pGEM-L plasmids, which encode the P, the N, and the L 
proteins of VSV, respectively, have been described previously (Pattnaik & Wertz, 1990).  
The plasmid pGEM-PeGFP, which encodes PeGFP fusion protein has been reported 
previously (Das et al., 2006) . All these plasmids were in pGEM-3 vector (Promega) 
under the control of T7 RNA polymerase promoter. For expression of these proteins by 
cellular RNA polymerase II (Pol II) promoter, the entire protein coding sequences from 
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the above plasmids were released by restriction digestion and sub-cloned in plasmids 
where the  expression of the viral proteins is under the control of cytomegalovirus 
immediate early (CMV IE) promoter. The N, P, and the L coding sequences released 
from the respective plasmids were cloned in pHygEGFP vector (Clontech, Mountain 
View, CA), replacing the hygromycin-eGFP fusion protein coding sequences. These 
plasmids were termed pHE-N, pHE-P and pHE-L, respectively. Additionally, PeGFP, P, 
and L coding sequences were sub-cloned in pcDNA 3.1-neo vector (Invitrogen) under 
CMV promoter. These plasmids were named pc-PeGFP, pc-P, and pc-L, respectively.  
2.9.2 Construction of a plasmid expressing N, P and L 
To construct a plasmid encoding all three proteins (N, PeGFP, and L) of VSV in 
tandem, the coding sequences of P along with upstream CMV promoter and downstream 
poly (A) signal sequences were released from pHE-P plasmid by digesting with BglII and 
NaeI and this fragment was made blunt by treating with Klenow (New England Biolabs). 
This blunt-ended fragment was inserted in pHE-N plasmid at NaeI site, which is located 
downstream of poly (A) signal sequences and the resulting plasmid was named pHE-NP. 
The coding sequences of P in pHE-NP were replaced with coding sequences of PeGFP 
from pGEM-PeGFP. The resulting plasmid was termed pHE-NPeGFP. Subsequently, the 
N and PeGFP coding sequences with their corresponding CMV promoters and poly(A) 
signal sequences were released from pHE-NPeGFP by digestion with DraIII and XmnI 
and inserted at the unique BstZ17I site located downstream of  the SV40 poly(A) signal 
sequences in the pc-L plasmid. This final plasmid was termed pc-NPeGFPL, which 
contains the coding sequences for all the three VSV proteins. The expression of all the 
three VSV proteins is under the control of independent CMV promoters and poly (A) 
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signals in the pcDNA vector that also carries the neomycin phosphotransferase gene for 
selection of transfected cells with G418.  
2.9.3 Construction of mini replicon of VSV 
Previous works from our lab reported the construction and use of positive sense 
mini replicons of VSV (Das & Pattnaik, 2005). To circumvent the issue of transcription 
from cryptic promoter, negative sense minireplicon with eGFP as reporter gene was 
constructed (Nayak et al., 2009). The eGFP mini replicon was under the control of T7 
promoter. Two unique restriction sites (BsiWI and KasI) were engineered in this negative 
sense mini replicon to place two different reporter genes. These restriction sites flank 
VSV gene specific initiation and termination signals as well as leader and trailer 
sequences. To generate authentic 5‟ and 3‟ termini after transcription by CMV promoter, 
hammerhead ribozyme and hepatitis delta ribozyme were placed before trailer and after 
leader sequences respectively. The base replicon without any reporter gene to pHygeGFP 
plasmid was transferred to p Hyg-eGFP vector where the transcription of the 
minireplicon was under CMV promoter. EcoRI and NotI enzymes were used to cut the 
Hyg-eGFP portion from the vector plasmid and base replicon was cloned back at these 
sites. The plasmid “p-base replicon” does not contain any gene in both the BsiWI and 
KasI sites is considered as empty base replicon. The hygromycin gene was PCR- 
amplified with KasI site and cloned into the KasI site in the base replicon. This plasmid 
was named as p-Hyg replicon. Subsequently the mRFP gene was amplified by PCR and 
cloned into the BsiWI site. The resultant plasmid was named as p-RFP-Hyg Replicon. 
Sequences and orientations were then verified by sequencing the plasmid.  
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2.9.4 Construction of a sub-genomic replicon of VSV 
The VSV sub-genomic replicon was also constructed based on the negative sense 
minimal replicon.  In this sub-genomic replicon, VSV-G and M protein coding sequences 
were removed to disable infectious virus production. Full length VSVPeGFP construct 
generated in our laboratory (Das et al., 2006) was used as a template for further 
modification. The M and G coding sequences together were deleted from VSVPeGFP 
using SnaBI and NheI, and Neomycin phosphotransferase gene was cloned using these 
sites. Sequence of Neo
R
 was verified by sequencing. To generate a negative sense 
replicon, N-PeGFP-Neo sequences were PCR amplified and cloned into the BsiWI site of 
the negative sense base replicon. The resultant plasmid was named as p-N-PeGFP-Neo 
replicon. L coding region was cut from the plasmid and made blunt.  p-N-PeGFP-Neo 
replicon was digested with KasI, made blunt and blunt ended L fragment was inserted 
into this site. Orientation was verified by restriction enzyme digestion and sequencing. 
This final construct was termed as pN-PeGFP-Neo-L replicon.  
2.10 Plasmid DNA transfection 
Plasmids were transfected using Lipofectamine 2000 (Invitrogen) or Fugene 
(Roche) according to manufacturers‟ instructions.  
2.11 Establishment of stable cell line expressing N, PeGFP and L 
HEK-293 cells in 35mm tissue culture plates were transfected with pc-NPeGFPL 
plasmid or empty vector pcDNA3.1-Neo using Lipofectamine 2000. After 48 hours of 
transfection, cells were trypsinized and 25% of the cells were plated in 60 mm cell 
culture dishes. After 16 hours, the cells were subjected for drug selection with 1mg of 
G418 per ml of growth medium. Media in the culture dishes were replaced every 48 
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hours with fresh media containing the same concentration of G418 until drug resistant 
cells appeared. Empty-vector transfected G418 resistant cells not expressing the viral 
proteins served as control cells. Roughly 15% to 20% of cells in the culture transfected 
with pc-NPeGFPL plasmid expressed green fluorescence as judged by fluorescence 
microscopic examination of the culture. The green fluorescent cells were enriched by 
multiple rounds of growth and cell sorting by fluorescent assisted cell sorter (FACS, 
FACSVANTAGE SE, Becton Dickinson) until greater than 90% of the cells in the 
culture expressed green fluorescence. Subsequently, for isolation of stable cell clones, 
individual cells positive for PeGFP expression were sorted by FACS into 96-well tissue 
culture plates. Individual cells were then grown, expanded, and analyzed by 
immunofluorescence for expression of the N and the L proteins. Several cell clones 
expressing all the three proteins were then identified for further studies.   
2.12 Metabolic labeling and immunoprecipitation of protein 
HEK-293 cells grown in 60mm cell culture dishes were transiently transfected 
with appropriate plasmids. At 48 hours post-transfection, cells were starved in cysteine 
and methionine free media for 1 hour and radiolabeled with 50 μCi of Expre35S35S 
protein labeling mix per ml of cysteine- and methionine-free medium for 6-8 hours. 
Preparation of cell extracts, immunoprecipitation with various antibodies, sodium 
dodecyl
 
sulfate-10% polyacrylamide gel electrophoresis (SDS-10%PAGE) analysis,
 
and 
detection of proteins by fluorography were carried out as
 
described previously (Pattnaik 
& Wertz, 1990). Stable cell clones expressing the viral proteins were grown in 6-well 
culture plates and the proteins were radiolabeled for 6-8 hours as described above and 
detected by immunoprecipitation and SDS-PAGE.  
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2.13 Metabolic labeling and analysis of RNA after DI particle infection 
NPeGFPL stable cells grown on 60mm culture dishes were infected with DI 
particles of VSV  (5 µl of DI stock per 60 mm dish) and immediately radiolabeled with 
50 μCi 3H-uridine per ml of medium for 20 hours. Cell extracts were immunoprecipitated 
with anti-N antibody, radiolabeled RNAs were recovered from immunoprecipitated 
complexes by phenol:chloroform extraction and analyzed by electrophoresis
 
in acid-
agarose-urea gels, and detected by fluorography. DI RNA replication in BHK-21 cells 
transiently expressing the viral proteins by T7 RNA polymerase was performed as 
described previously (Pattnaik & Wertz, 1990).  
2.14 Luciferase assay 
Stable cells expressing N, PeGFP, and L proteins or control cells not expressing 
the viral proteins were co-transfected with 0.4 μg of IFNβ-Luc or ISRE-Luc or pGL4.32 
(Luc2p/NFκB-RE/Hygro)  along with 10 ng of pRL-TK using Fugene 6 (Roche Applied 
Science) as per manufacturer‟s protocol. The pRL-TK vector (Promega), which contains 
renilla luciferase reporter gene under the control of herpes simplex virus thymidine 
kinase (TK) promoter, serves as an internal control for transfection efficiency. At 24 
hours post-transfection, the cells were either mock-infected or infected with DI particles. 
At 16 hours post-infection, the cells were lysed in lysis buffer (Promega) and luciferase 
assay was performed using Dual Luciferase assay kit (Promega). Luciferase activities 
were expressed as fold change over control uninfected cells after normalizing with renilla 
luciferase activity.  
2.15 Reverse transcription (RT) PCR to detect DI particle genome  
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For RT-PCR detection of DI RNA, DI particle infected 293-NPeGFPL cells 
grown in six well plates were lysed in Trizol (Invitrogen). RNA was extracted as per 
manufacturer‟s recommendation and resuspended in 10 μl of water. Four μl of RNA was 
used for reverse transcription in total 10 μl volume. Superscript III (Invitrogen) was used 
for reverse transcription.  The reaction mixture contained 4.0 μl of RNA, 0.5 μl of SS III 
RT, 1 pmole of primer, 2 μl of RT buffer, 0.25 μl of RNAsin (New England Biolab). 
First- strand synthesis was carried out at 50
oC for 1 hour. Because both 3‟ and 5‟ termini 
sequences are complementary, only one primer was used for first strand synthesis as well 
as PCR amplification of the cDNA. The primer sequence is 5‟ACGAAGACCAC AAA 
ACCAGATAAAAA 3‟.  The PCR amplification was carried out using Taq DNA 
polymerase (New England Biolab). The reaction mixture contained cDNA 5 μl, 10 X Taq 
polymerase buffer 5 μl, Primer 4 μl (4 pmole), 1 μl of Taq DNA polymerase in a 50 μl 
reaction condition.  The cycling conditions were as follows; initial denaturation at 94
0
C 5 
minutes, denaturation at 94
o
C for 30 sec, annealing 52 
o
C for 30 sec, extension 72
o
C for 2 
minutes 30 sec for 35 cycles and final extension at 72
o
C for 10 minutes.    
2.16 Quantitative RT PCR 
Quantitative reverse-transcription PCR (qRT-PCR) was used to measure the VSV 
P mRNA as well as genome and anti-genome in experiments involving siRNA mediated 
gene knockdown. Total RNA was extracted from one well of a 12-well tissue culture 
plate by Trizol (Invitrogen) according to manufacturer‟s protocol. First-strand cDNA was 
synthesized using M-MLV RT (Invitrogen) and 200 ng of total RNA was used in 20 μl 
reaction volume. For quantification of P mRNA and beta-actin mRNA, 1 μl of oligo –
(dT) was used. For anti-genome, VSV 2955-R primer (2pmole/ μl) and B-actin1 R primer 
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(2pmole/ μl) was used. First strand synthesis was performed according to M-MLV RT 
protocol provided by the manufacturer. The sequences of the primers and probes are 
given in Table 2. 1.  qRT-PCR was optimized with different concentrations of primers 
and probes in Cepheid Smart cycler (Cepheid, CA, USA). Final concentrations of primers 
and probes are listed in Table 2.2. The thermal set up for the PCR was done as follows, 
initial denaturation was done at 95
o
C for 5 minutes, denaturation at 95
0
C for 30 seconds, 
annealing and extension at 60
o
C for 30 sec. Total amplification cycles were 40. Fold 
change was obtained using a ∆∆CT method after normalizing with the non targeting 
siRNA treated sample.  
2.17 Immunoblotting 
For western blotting, cells (12 well or six well format) were washed with cold PBS once. 
Cells were collected in cold PBS after scrapping with a cell scrapper and pelleted at 
10000 RPM for 5 minutes. Supernatant was aspirated out and cells were pelleted and 
lysed using 20 μl RIPA buffer (10Mm Tris pH 8.0, 140 mM sodium chloride, 1.0% 
Triton X 100, 1.0% sodium deoxycholate, 0.1% sodium dodecyl sulfate along with 
protease inhibitons such as 2mM PMSF, 1mM Leupeptin). To facilitate lysis, cells were 
frozen and thawed, vortexed and again pelleted at 13000 RPM for 20 minutes. 
Supernatant was collected into a fresh tube. Protein was quantified using Bradford 
reagent (Biorad, Catalog # 500-0006). Equal amounts of proteins were separated by SDS-
polyacrylamide (SDS-12% PAGE) gel except for GBF1 experiment where 4-20% 
gradient gel (BioRad) was used. After separation, proteins were transferred to a PVDF 
membrane by semi-dry transfer or wet transfer.  
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Table 2.1: Sequences of Primers and Probes 
 
Table 2.2: Optimized concentrations of primers and probes 
 
  
VSV2795F GTGACGGACGAATGTCTCATAA
VSV2860R TTTGACTCTCGCCTGATTGTAC
VSV2955R TGATGAATGGATTGGGATAACA
BActin-F CAAGTACTCCGTGTGTGGAT
BActin-R CATACTCCTGCTTGCTGAT
VSV 2825 probe 6-FAM/CCATCCTGCTCGGCCTGAGATAC/TAMRA
B Actin probe Cy5/TCGCTGTCCACCTTCCAGCAGAT/BHQ2
Primers Primer Concentrations Probe Probe 
Concentrations
VSV P mRNA VSV2795-F 500 nM VSV2825 200 nM
VSV2860-R 500 nM
VSV Anti-genome
Or Genome
VSV2795-F 1000 nM VSV2825 200 nM
VSV2955-R 1000 nM
Human B-actin B-actin-F 500 nM B actin Probe 1000 nM
B-actin-R 500 nM
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 Membranes were blocked with blocking buffer (5% skim milk with PBS and 0.05 % 
Tween 20). Membranes were probed with primary and corresponding secondary 
antibodies.The same membranes were stripped and re-probed with another primary 
antibody. VSV M monoclonal antibody was used to detect viral M protein. Anti-actin 
antibody was used to detect beta-actin as a loading control.  
2.18 High-throughput assay for primary screen 
2.18.1 siRNA Library Design 
The screen was performed at the Duke University using the Qiagen genomic 
siRNA library v 1.0. The genomic siRNA library was arrayed in 384-well micro plate 
format.  The library consisted of 4 distinct siRNAs (A, B, C and D) targeting 22909 
known and putative human genes. Four siRNA were divided into pool of 2 with each 
pool containing 2 unique siRNA duplexes (set AB and set CD). This format resulted in 
74 micro plates for each set and total 148 plates. This 2 X 2 pool design allowed each 
gene to be tested by two independent siRNA sets. All stars non targeting siRNA (Qiagen) 
was used as a negative contol which did not affect the levels of any of the known or 
putative human gene products. Also siRNAs targeting to N and L gene of VSV were 
synthesized and used as additional control siRNA to verify transfection efficiency. The 
sequences of the siRNAs targeting VSV genes are as follows  
N1 5‟ CUGCAAGGCCUAAGAGAGA 3‟ 
N2 5‟ UGGAAUACCCGGCAGAUUA 3‟ 
L1 5‟ GCAGUUAUCCAGCAAUCAU 3‟ 
L2 5‟ GAGAAACGUUGUAGAAUUA 3‟ 
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All the control siRNAs were manually added to the designated wells during screen.   
2.18.2 Primary screen assay optimization 
Assay optimization was the longest part of the screen. Corning 384-well black 
tissue culture plates (Catalog # 3712) were pre-arrayed with 1 p mole of siRNA using a 
velocity Bravo liquid handling system (Agilent technologies, CA).  Reaction conditions 
for the screen such as the cell line, cell number, siRNA concentration, amount of 
Lipofectamine RNAi MAX to be used, control siRNAs to be used in the screen, 
multiplicity of infection (MOI), incubation period after infection, desired percent 
infection were optimized empirically by series of experiments conducted at the Duke 
University RNAi Screening center. A test screen with one genomic siRNA library plate 
and a pilot screen with three sets of genomic screen plate (three plates from AB pool and 
corresponding three plates from CD pool) were conducted to assure the validity of the 
screen. HeLa cells (CCL2, ATCC, Manasass, VA) was used for the assay. After 
optimization, 3000 cells per well was used for transfection. Transfection of the cells was 
done with 15.4 nM final concentration of siRNAs in a 65 μl of total volume. 
Lipofectamine RNAiMAX (Invitrogen, CA) was used as transfection reagent in the 
amount of 0.05μl per well in 10 μl of OptiMEM (Invitrogen, CA). Each ptate contained 
siRNAs targeting VSV N and L gene as control siRNAs to determine transfection 
efficiency. VSV-eGFP virus grown in BHK-21 cells and titrated in HeLa cells was used 
at 0.5 MOI. This particular MOI when infected in 25 μl volume in one well of a 384 well 
plate, resulted in approximately 60% infection after 18 hrs of infection. To identify 
factors involved in all stages of VSV life cycle such as entry, uncoating, replication and 
budding, the screen was standardized with a multiplicity of infection and time to allow 
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multiple rounds of virus infection. During assay optimization, it was observed that 0.5 
MOI of virus in 25 μl volume resulted in second-round of virus infection and gene 
expression after 10 hours post infection. Therefore, percent infection (60-70%) at 18 
hours post infection was considered a result of multiple rounds of virus infection.    
2.18.3 Automated determination of cell number and percentage infection 
At the end of the infection, cells were fixed with 4% paraformaldehyde in PBS for 
15 minutes, permeabilized with 0.1% triton-X 100 in PBS for 15 minutes and stained 
with Hoechst 33342 in PBS for 30 minutes. Stained cells were imaged with a Cellomics 
ArrayScan VTI automated microscope. Images were analyzed with vHCS Scan Target 
Activation software v 5.1.2 to identify infected cells. Cells without VSV-eGFP infection 
served as control population for background fluorescence. Four fields per well of a 384 
well plate were imaged at 10X magnification. First, cells were identified by their nuclei 
staining in channel 1 of Cellomics. Cells those passed the criteria were analyzed for GFP 
expression in channel 2. GFP intensity was calculated for each and every individual cell 
in the field. Frequency distribution of GFP-intensity was plotted and compared between 
NT controls infected with VSV-eGFP and uninfected control. For selection of infected 
cells, gates were set by manual inspection of representative images from VSV-eGFP 
infected and uninfected cells. Cells appearing at least 5 standard deviations away from 
the average intensity of uninfected control population in the same plate or same batch 
were considered positive for GFP expression. Once the gate was determined, all the 
plates were subjected for data analysis by vHCS Target activation software. Finally, data 
was obtained using vHCS View software v 5.1.2 and the numbers of cells present in the 
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well were identified as “Valid Object Count” whereas the percentage of infection was 
determined as “% selected”.  
2.19 Protocol for primary Screen 
2.19.1 Transfection 
Primary screen was conducted using HeLa cells (CCL2, ATCC). HeLa cells 
between 30 and 40 passages were used. Per day, 14 microplates were transfected and the 
procedures for screening all the 148 plates were completed within a span of 14 days.  
Cells were continuously cultured to maintain a supply of cells for the transfection. The 
following protocol describes the work flow for transfection for each day. Before thawing 
the assay plates, cells were examined for viability. Assay plates were thawed for 15-20 
minutes at room temperature. Then the plates were centrifuged at 500 g for 4 minutes. 
Control siRNAs 5 μl each of All stars NT, N1N2, L1L2 (200 nM stock) were added to 
the designated wells manually. OptiMEM and Lipofectamine RNAi MAX mix was 
prepared in a sterile container. Ten μl of mix was added to each well using a Well Mate 
dispenser (Thermo Scientific). Plates were centrifuged at 300 g for 30 sec and incubated 
at room temperature for siRNA and Lipofectamine complex formation. While the plates 
were being incubated, cells were trypsinized, counted and resuspended as per the 
requirement. Diluted cells at a concentration of 3000 cells in 50 μl volume per well were 
added using the Well mate dispenser (Thermo Scientific). Cells were further incubated 
for 52 hrs to allow the knock-down of genes.   
2.19.2 Virus infection 
After 52 hours of transfection, VSV-eGFP infection was done at an MOI of 0.5 
MOI. Virus suspension was prepared in DMEM 2% FBS and PKS in a sterile bottle. 
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Temperature of DMEM was approximately 18-20
o
C at the time of addition of virus. 
Transfected media from the wells were aspirated by the Biotek ELx 405 automated plate 
washer (Biotek, VT, USA). Virus inoculum (25 μl) was added per well with the help of a 
Matrix automated multichannel pipette (Thermo Scientific). Plates were centrifuged at 
300 x g for 30 sec and infection was done for 18hrs.  
2.19.3 Fixing and staining 
After 18 hrs of infection, infected media was aspirated using the Biotek ELx405 
plate washer. Cells were fixed with 4% paraformaldehyde in PBS using a Matrix 
automated multichannel pipette (Thermo Scientific). After 15 minutes of fixation, cells 
were washed with PBS using the plate washer.  Triton X-100 (0.1% in PBS) was used to 
permeabilize the cells. Cells were subsequently stained for 30 minutes with Hoechst 
33342 to stain the nuclei. Finally all the wells were filled with 50 μl of PBS after washing 
the Hoechst stain and the plates were sealed and were imaged with the Cellomics 
ArrayScan.   
2.19.4 Statistical analysis 
Sum rank statistics was applied to identify the hits from the primary screen. 
Because there was significant toxicity associated with the knockdown of some genes, 
wells where the cell number was less than 800 (VOC less than 800) were discarded from 
further analysis. The average cell number in the non targeting siRNA treated wells was 
3000. Below 800 cell number, the data analysis became erroneous and it could have 
potentially created difficulty for further validation of genes. After comparing control 
siRNA, batch-wise analysis (with plates used in one day) rather than genomic analysis 
was used to get the primary hits. The reason for this is that the non-targeting siRNA 
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treated controls were showing similar percent infection with a minimal standard deviation 
in a batch. There were batch to batch (i.e., day to day) variations in percent infection of 
non-targeting control samples and hence, batch wise analysis was more accurate in this 
context.  Percent infection values for set AB and set CD were ranked from lowest to 
highest and given ranks from 1 to n (n= number of samples analyzed) respectively. Sum 
rank is summation of ranks for corresponding pairs of set AB and set CD. The p value for 
each pair was determined and finally samples were aligned according to the p value. Two 
hundred genes with the lowest p values were identified as primary candidate hits 
(p<0.01). Another issue was emergence of numerous ribosomal subunit genes as potential 
candidates affecting VSV infection. Since ribsomes are required in general for cellular 
and VSV mRNA translation, their impact on virus infection was obvious. The ribosomal 
sub units were therefore omitted from the data analysis.  
2.20 Validation screen assay design 
The hits obtained by the primary screen had at least two independent siRNAs 
showing similar effect in VSV infection. In a high-thoughput siRNA screen a gene is 
called a true hit if two independent siRNAs show similar phenotype. However in order to 
avoid false discoveries and minimize off target effects, siRNA from a different source 
was used for secondary validation. Thus the validation screen was done with Dharmacon 
On Target Plus pool of 4 siRNA (Dharmacon, CO, USA).  Using siRNA from a different 
manufacturer, bias in siRNA design or target seed match can be avoided. The sequence of 
Dharmacon siRNAs did not overlap with that of Qiagen siRNAs. The assay plate format 
was also changed to 96-well format to increase the number of cells transfected and 
infected to increase the statistical power.  
50 
 
 Six μl of pooled siRNA (500nM) was pre-arrayed per well in 96-well plates using 
the Biomek FX liquid handling system at UNMC Eppley Cancer Center (Omaha, NE). 
Before transfection, plates were thawed and centrifuged at 500 g for 2 minutes to collect 
the siRNA at the bottom of the wells. Lipofectamine RNAi MAX and OptiMEM mix was 
prepared (0.25 μl of Lipofectamine RNAi MAX in 20 μl OptiMEM per well). 
Lipofectamine mix was added to the siRNA by a multichannel pipette. Plates were 
centrifuged at 500 g for 1 minute and incubated at room temperature for 30 minutes. 
HeLa cells were trypsinized and counted. For VSV infection 15,000 cells per well were 
added to each well in 75 μl of DMEM with 10% FBS and 1X PKS to yield a final 
concentration of 30 nM siRNAs. For LCMV and HPIV infection, 10,000 cells per well 
were added in 75 μl of growth media. Cells were incubated for 50 hrs for knockdown of 
the genes. For VSV-eGFP infection, 0.05 MOI of virus was added in 100 μl of DMEM 
2% FBS and 1X PKS per well using a multichannel pipette. Plates were centrifuged at 
300 g for 30 sec and incubated for 16 hrs for the infection to progress. LCMVr3-GFP 
(0.05 MOI) and HPIV-GFP (0.2 MOI) was used to infect HeLa cells. Virus inolculum 
containing required MOI of viruses were prepared in 40 μl of DMEM (with 5% FBS and 
PKS) per well. After 1 hr of infection, 60 μl of DMEM with 5% FBS and 1X PKS was 
added to each well and further incubated for 41 hrs for the infection to progress. Row A 
of the plate was not infected and this served as uninfected control for image analysis. 
Infected cells were fixed as per the protocol described in the primary screen. Cells were 
stained with DAPI to stain the nuclei. Image analysis was done in Cellomics ArrayScan 
VTI at UNMC, Eppley Cancer Center to obtain the “valid object count” and “% 
infection”.  Experment was repeated four times for VSV and two times each for LCMV 
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and HPIV. Candidates were identified using Wilcoxon Mann Whiney U test (Rank sum 
test) using median normalized value.  
2.21 siRNA transfection in six well or twelve plates 
Reverse transfection of siRNA was performed in 6-well or 12-well tissue culture 
plates. Final concentrations of siRNAs were 5nM (COPI sub units and GBF1) or 30 nM 
(ARF1). Required amount of siRNAs were plated in the 12- well of 6-well plates.  
Lipofectamine RNAiMAX in OptiMEM was prepared (2 μl of lipofectamine in 300 μl of 
OptiMEM per well) and added to the wells. Plates were incubated for 30 minutes for 
complex formation. HeLa cells were trypsinized, counted and 200,000 cells per well in 
500 μl of DMEM 10% FBS+ PKS were added for COPI experiments. For GBF1 and 
ARF1 experiments 100,000 cells were added. Cells were further incubated for 42-44 
hours for COPI depletion and 66-68 hours for GBF1 and ARF1 depletion.  
2.22 Immunofluorescene 
Cells were either fixed with 4% paraformaldehyde in PBS at room temperature 
for 15 minutes or cold methanol and acetone (50:50) for 10 minutes. Permeabilization 
was done by 0.1% Triton X 100 in PBS for 10 minutes. Permeabilized cells were blocked 
with 2% bovine serum albumin in PBS Tween 20 (0.05% Tween 20 in PBS). For 
labeling, cells were incubated with primary antibody inside a humidified chamber for 1 
hour. After three successive washings, appropriate secondary antibodies were added and 
incubated for 45 minutes. After five washings, cells were stained with DAPI whenever 
required and mounted in aqueous mounting media.  Cells were imaged by Olympus 
Inverted Confocal microscope at UNL microscopy core facility.  
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2.23 Antibodies 
Anti-VSV antibody has been reported previously (Li & Pattnaik, 1999). Anti-N 
monoclonal antibody and anti-M monoclonal antibody producing hybridoma cells 23H12 
were obtained from Douglas Lyles (Lefrancois & Lyles, 1982; Lyles et al., 1992). Anti-L 
rabbit polyclonal antibody was a gift from Manfred Schubert (Schubert et al., 1985). 
Anti- human ISG56 antibody was obtained from S. Sarkar (Guo et al., 2000).  
Commercial antibodies such as anti-actin (Sc-47778, Santa cruz biotechnology), anti-
eGFP (Sc-9996, Santacruz), anti-Renilla reniformis GFP (K 17, Santacruz), anti-beta 
COP (maD, Sigma), zeta COP (31-45, Sigma) and anti-ARF1 (Sigma) and anti-GM130 
monoclonal (BD science) and anti-GBF1 monoclonal (BD science) were purchased.   
2.24 Chemicals 
 Bafilomycin A1, Brefeldin A, Golgicide A, Tyrphostin AG1478 and CBM were 
purchased from Sigma.  
2.25 Treatment of cells with chemicals 
Stock concentration of Brefeldin A was prepared in ethanol where as DMSO was 
used to prepare the stock solutions of Bafilomycin A1, Golgicide and AG. Working stock 
solution of CBM was prepared in water. HeLa cells were treated with drugs before or 
after VSV infection.  
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CHAPTER III 
GENERATION AND CHARACTERIZATION OF CELL LINES EXPRESSING 
VSV REPLICATION PROTEINS AND ATTEMPTS TO ESTABLISH A CELL 
LINE CARRYING SELECTABLE SUB-GENOMIC REPLICONS OF VSV 
 
 
 
 
 
 
 
 
 
 
 
 
Part of the work described in this chapter was published in Journal of Virology, 2010.  
 
Debasis Panda, Phat X Dinh, Lalit K. Beura and Asit K. Pattnaik, 2010. Induction of 
Interferon and Interferon Signaling Pathways by Replication of Defective Interfering 
Particle RNA in cells Constitutively Expressing Vesicular Stomatitis Virus Replication 
Proteins. J Virology, 84 (9): 4826-4821.  
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3.1 Construction of a cell line constitutively expressing VSV replicon proteins  
N, P and L are the replication proteins for VSV. Presence of N, P and L is 
sufficient to replicate the sub-genomic particles for VSV (Pattnaik & Wertz, 1990).  
Plasmids where the expressions of N, P and L were driven by cellular pol II (CMV) 
promoter were constructed.  Protein expression from these plasmids was verified by 
labeling with 
35
S and immunoprecipitation with anti-VSV antibody (Fig 3.1). To 
determine if the proteins are functional in supporting replication of VSV DI particle 
genomes, the 293 cells that had been transiently transfected with the three plasmids were 
infected with DI particles and replication of DI particle genome was examined. Our 
results show that the expressed proteins are functional in replicating the DI particle RNA 
genome (data not shown). The level of DI RNA replication supported by the proteins 
expressed by cellular Pol II was reproducibly less than that obtained in the vaccinia virus-
T7 polymerase expression system. We reasoned that it might be possible to obtain higher 
levels of replication, if all the VSV proteins are expressed from a single vector resulting 
in the expression of all three proteins in the same cell. Therefore, we constructed a 
plasmid in which the coding sequences for N, PeGFP, and L are under the control of 
separate CMV promoter and poly (A) sequences. This plasmid (pc-NPeGFPL, Fig. 3.2) 
expressed N, PeGFP, and L proteins in readily detectable amounts (Fig. 3.1, lane 5) and 
supported replication of DI particles (data not shown) at levels higher than that of three 
plasmid system but at a level approximately 15-20 % of that seen in the vaccinia virus-T7 
polymerase system.  
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Figure 3.1:   Transient expression of VSV proteins by CMV promoter. Cells were 
transfected with plasmids pHE-N (lane 2), pc-PeGFP (lane 3), or pHE-L (lane 4) 
encoding the individual viral proteins or the plasmid pc-NPeGFPL (lane 5) encoding the 
three viral proteins or the empty vector (lane 1) as shown on top of each lane. After 48 
hours of transfection, cells were radiolabeled with Expre
35
S
35
S label for 8 hours and the 
radiolabeled proteins were immunoprecipitated with anti-VSV antibody, analyzed by 
SDS-PAGE, and detected by fluorography. Total lysates from cells infected with VSV-
PeGFP (lane 6) or wild-type VSV (lane 7) were labeled and analyzed similarly to identify 
the virus-specific proteins. Positions of VSV proteins are shown on the right. 
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In order to generate stable cell lines expressing the three replication proteins of VSV, 293 
cells were transfected with pc-NPeGFPL plasmid. This plasmid also encoded neomycin 
phosphotransferase gene for selection of transfected cells in the presence of G418. At 48 
hours post-transfection, the cells were treated with G418. The drug resistant culture was 
then enriched for cells expressing PeGFP fluorescence by FACS. Immunofluorescent 
staining of these cells for expression of the N and L proteins demonstrated that the 
majority of the green fluorescent cells also expressed the N protein but only a small 
percentage (less than 5%) of the cells expressed the L protein (data not shown). To isolate 
cell clones expressing all three proteins, single cell sorting of  cells positive for PeGFP 
expression was performed by FACS into 96-well tissue culture plates, with each well 
having one cell. Each expanded clonal population of cells was then analyzed for 
expression of L protein as well as N protein by immunofluorescent staining. These cells 
were also examined for expression of the viral proteins by radiolabeling and SDS-PAGE 
analysis. Additionally, most cell clones that expressed all the three viral proteins were 
also screened for their ability to support replication of the DI particle genome (data not 
shown).  Based on these initial screening results, three cell clones (293-pcNPeGFPL cell 
clone # 204, 206, and 211) were selected for further studies. Immunofluorescent staining 
of the cells derived from the clone # 204 showed that all the three viral proteins were 
expressed in majority of the cells in the culture (Fig.3.3). 
Although, the levels of PeGFP or the N proteins in individual cells in the culture 
appeared to be similar, the L protein expression was somewhat variable from cell to cell. 
Similar variability in the expression of L protein was also seen in cells derived from the 
two other cell clones (data not shown). Examination of the expression of N, PeGFP, and 
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Figure 3.2: Schematic representation of the plasmid expressing the VSV N, PeGFP, 
and L proteins. Coding sequences of N, PeGFP and L were cloned under the control of 
CMV immediate early promoter and poly(A) signal in pcDNA 3.1-neo vector. The CMV 
promoter and poly(A) signal sequences for N and PeGFP were derived from pHygEGFP 
vector. Coding sequences of N, PeGFP and L are shown in blue, green, and red, 
respectively. Ampicillin resistant gene (Amp
R
), neomycin resistant gene (Neo
R
) and 
SV40 promoter and origin of replication (O), CMV promoter (pCMV), and 
polyadenylation signal sequences (pA) are shown. 
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L proteins in these clones by radiolabeling, immunoprecipitation, and SDS-PAGE 
analysis revealed that each of these cell clones expressed readily detectable levels of the 
three viral proteins (Fig. 3.4).  
3.2 Efficient replication of DI particle genomes in cells stably expressing the VSV 
replication proteins  
To test the functionality of proteins expressed by these stable cell clones, the cells 
were infected with DI particles of VSV and checked for the replication of DI particle 
RNA. Results show that each of the cell clones supported efficient replication of the VSV 
DI particle genome (Fig. 3.5 A). The level of DI genome replication in the three cell 
clones (lanes 3-5) was comparable to that seen in the vaccinia virus-T7 system (lane 1). 
These results suggest that the replication proteins of VSV can be constitutively expressed 
in a cell and they can form functional polymerase complex to support the replication of 
DI particles of VSV.  
 To examine the stability of expression of all the 3 VSV proteins and long term 
effects of expression of the VSV proteins on cell growth, the clonally isolated cells were 
monitored for growth under culture conditions. After continuous passaging over six 
months (approximately 60 passages), examination of the stable cell clones # 204 and # 
206 showed relatively similar level of protein expression in these cell clones as compared 
to early passage cells (data not shown). Importantly, even after 6 months of passages of 
the cells in culture conditions, these cell lines supported efficient replication of DI 
particle RNA (Fig.3.5 B). These results suggest that constitutive expression of N, PeGFP, 
and L proteins has no adverse effects on cell viability or growth and that the cell lines can 
be maintained for long time without any adverse effect on the levels of protein expression  
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Figure 3.3: Detection of VSV proteins in stable cell clones by immunofluorescence.  
Cells from stable cell clone # 204 were simultaneously immunostained with anti-N 
monoclonal antibody (10G4) and anti-L antibody and subsequently with donkey anti-
mouse Alexa 647 and goat anti-rabbit Alexa 594 secondary antibodies. Cells were 
mounted and observed under inverted confocal microscope. Epifluorescence microscopy 
of cells expressing PeGFP (panel a); immunofluorescent images of the same cells 
expressing the N (panel b, pseudo color blue) and the L protein (panel c, red). Panel d 
shows the merged images of panels a, b, and c. DIC image of the cells is shown in panel 
e. 
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Figure 3.4: Expression of VSV proteins in different cell clones. G418 resistant stable 
cell clones # 204, 206, and 211 (lanes 2-4) as well as pcDNA3.1 vector transfected stable 
293-pcDNA cells (lane 1) were radiolabeled with Expre
35
S
35
S protein labeling mix. The 
radiolabeled proteins were immunoprecipitated with anti-VSV antibody, analyzed by 
SDS-PAGE, and detected by fluorography. Radiolabeled proteins from HEK293 cells 
infected with VSV-PeGFP (lane 5) or wild type VSV (lane 6) cells are also shown. Viral 
proteins are identified on the right.  
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Figure 3.5:  Replication of DI particle RNA genome in 293-NPeGFPL cell clones.  
(A) Cell clones # 204, 206, or 211 (lanes 3-5, respectively) or 293-pcDNA control cells 
(lane 2) grown in 60 mm dishes were infected with DI particles and radiolabeled with 
3
H-
uridine. Radiolabeled DI RNA was recovered from cell extracts by immunoprecipitation 
with anti-N antibody and analyzed by agarose-urea gel electrophoresis and detected by 
fluorography as described previously. Lane 1 shows DI RNA replication products 
obtained in BHK-21 cells using the vv-T7 system. DI RNAs (– and + sense) are 
identified on the right. (B) DI RNA replication in stable cell clones after 60 passages 
(approximately six months) in culture. Experimental protocol was the same as in panel A. 
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or protein function.   
3.3 Failure to demonstrate persistent DI particle replication using the NPeGFPL 
stable cell line 
After generating a cell line which supports DI particle replication efficiently, next 
objective was to establish a cell line where DI particles replicate on a long- term basis. 
Previously, for Sendai virus it has been shown that DI genomes can be maintained in 
helper cell lines expressing N, P and L protein of sendai virus (Willenbrink & Neubert, 
1994). To establish similar type of cell line for VSV, the 293-NPeGFPL cells were 
infected with DI particles. Cells were further passaged every 2 days up to 12 passages. At 
each passage, samples were collected to examine DI genome product by reverse 
transcriptase PCR. DI RNA could be detected at 4
th
 passage by RT PCR whereas no DI 
genome could be detected by 6
th
 passage (Fig. 3.6). Repeated attempts to maintain DI 
genome replication persistently in such helper cell line failed. DI genome replication 
occurs in the cytoplasm. So in each cell division DI genomes also should be partitioned 
into the daughter cells. There was also no overt cytopathic effect exhibited on the cells 
due to replication of DI RNA. Failure to establish such a system indicates that DI genome 
can be maintained only for short term duration.  
3.4 Failure to demonstrate replication of a minimal replicon of VSV  
Another possibility of failure to establish a persistent DI RNA replication in 
helper cell line is lack of positive-selection. Defective interfering particle genome did not 
encode any drug resistance reporter gene, so cannot be used for selection. To circumvent  
63 
 
 
 
Figure 3.6 Long term replication of DI genome in NPeGFPL cells 
NPeGFPL cells (# 204) were infected with DI particles. After 24 hours of infection, cells 
were trypsinized and passaged further. Subsequently, cells were passaged after 48 hours. 
Cell lysate was collected in Trizol at each passage. RNA was extracted and presence of 
DI genome was examined by reverse transcriptase PCR.   
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this issue, a minimal replicon of VSV with two reporter genes as two separate 
transcription units was generated (Fig. 3.7 A). This plasmid contained mRFP gene as 
visual marker and hygromycin gene for drug selection. Figure 3.7 B depicts the rational 
for generating and using the minimal replicon. The replicon was under the control of 
CMV promoter. 293-NPeGFPL cell clone 204 was transfected with the mRFP-Hyg 
replicon. At 2 days post transfection, when the cells were observed under microscope, no 
red fluorescence could be observed suggesting low level or no replication of mini 
replicon. However after two days, Hygromycin B was added at 500μg/ml along with 
G418 500μg/ml. Cells were further passaged untill drug-resistant colonies appear. 
Recovery of cells resistant to both the drugs would be an indicator of possible replication 
and transcription of mini replicon. The cells were found dead by 6-8 days of drug 
selection. No drug- resistant colonies were observed even after 18 days of drug selection.   
3.5 Attempt to develop a cell line supporting replication of an autonomous replicon 
Parallel to the above approach, an autonomous replicon of VSV was also 
constructed and attempts were made to launch the replicon in 293 cells. The rational for 
generating the autonomous replicon was that the replicon encoding the viral replication 
proteins once assembled by the proteins provided by the helper plasmids, will 
subsequently be replicated by the proteins encoded in the replicon. Thus, the replicon will 
become independent of the helper plasmids and persistent replication will be established. 
The replicon should encode a drug selection marker; therefore positive selection can be 
applied to isolate the cells harboring the replicon. To generate such a cell line, a sub-
genomic replicon without M and G protein coding regions and with a Neo
R
 gene was  
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Figure 3.7:  Schematic of bicistronic mini replicon. A. Relevant components of the 
minimal replicon are shown. CMV, Cytomegalo virus immediate early promoter; pA 
SV40 polyadenylation signal; HH, hammerhead ribozyme; hepatitis delta virus ribozyme; 
Tr, VSV trailer; Le, VSV leader; mRFP, monomeric red fluorescent protein coding seq; 
Hyg, hygromycin resistant gene. B. Replication of bicistronic mini replicon. Resultant 
mini replicon transcript by CMV promoter is cleaved by HH and HDR. Subsequently this 
is encapsidated by VSV N protein and assembled into functional RNP. Replication by 
VSV polymerase will generate complementary sequence and transcription by VSV 
polymerase will express mRFP and confer hygromycin resistance.  
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generated (Fig 3.8). The principle of replication of sub-genomic replicon was similar to 
that of minimal replicon. The sub genomic replicon was transfected to HEK-293 cells 
along with N, P, and L expressing plasmids. The expression of N, P and L from the 
support plasmids are driven by CMV promoter. After 48 hrs of transfection, transfected 
cells were treated with G418 at a concentration 1mg/ml. Cells were sub cultured at 1: 4 
ratio and maintained in the presence of G418 at 1mg/ml. After 10 days of drug treatment 
few GFP expressing cells were observed. GFP-expressing cells were isolated from the 
plate by local trypsinization and grown further. Furthermore, GFP-expressing population 
was enriched by FACS. After 3 rounds of FACS sorting, a cell population where more 
than 50% of the cells were expressing GFP was achieved (Fig. 3.9). To examine possible 
replication of genome, cells were radiolabeled with 
3
H after actinomycin D treatment. 
Actinomycin D treatment blocks cellular mRNA transcription but has no effect on viral 
genome transcription. Repeated attempts to show VSV mRNA products were 
unsuccessful. However, PeGFP protein and N protein was readily detected in these cells 
by western blot analysis (data not shown).  The reason for the failure of VSV specific 
replication in presence of Actinomycin-D is unclear. It can be speculated that the replicon 
plasmid was integrated into the host chromosome and there was expression of PeGFP 
through a cryptic promoter despite the fact that PeGFP was in negative sense orientation 
to the CMV promoter. To alleviate this issue, the sub-genomic replicon was transferred to 
an episomlly replicating vector (pCEP4, Invitrogen). However, attempts to establish a 
replicon cell line using pCEP4 based replicon was also unsuccessful. 
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Figure 3.8:  Schematic of autonomous replicon. A. Relevant components of the 
autonomous replicon are shown. CMV, Cytomegalo virus immediate early promoter; 
HH, hammerhead ribozyme; hepatitis delta virus ribozyme; Tr, VSV trailer; Le, VSV 
leader; N, nucleocapsid protein; PeGFP, phospoprotein fused in frame with eGFP; L, 
large polymerase protein. Neo, neomycin phosphotransferase.  
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Figure 3.9: GFP expression in 293 cell line transfected with autonomous replicon 
HEK-293 cells were transfected with replicon plamid along with N, P and L expressing 
plasmid. Drug selection started after 48 hours of transfection. GFP-expressing cells were 
enriched  by FACS analysis.  A cell population expressing PeGFP protein is shown in the 
right. Left panel is phase contrast image of the same cells.   
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3.5 DI particle RNA replication activates IFNβ promoter  
Activation of dsRNA signaling and subsequent IFN production by both VSV and 
VSV DI particle has been well documented (Marcus & Gaccione, 1989).  Matrix (M) 
protein is the only protein encoded by VSV known to shut off host cellular mRNA 
synthesis and nucleo-cytoplasmic transport of RNAs and thereby inhibit IFN production 
(Ahmed & Lyles, 1998; Faria et al., 2005). The availability of vaccinia virus-free system 
that supports DI RNA replication provided us a unique opportunity to examine the effects 
of DI RNA on host cell functions, particularly, the activation of innate immune signaling 
pathways in the absence of the viral M protein. It was hypothesized that replication of DI 
particles of VSV might be activating the interferon response and thus after few passages, 
DI genomes are lost from the cell. To test this hypothesis, luciferase reporter system was 
used.  DI particle infection of the control cell line not expressing the viral proteins (293-
pcDNA) exhibited only basal level (1.3-fold) of IFNβ promoter activity over uninfected 
cells (Fig. 3.10). However, in 293-pcNPeGFPL cells expressing the replication proteins, 
DI particle infection and subsequent DI RNA replication resulted in activation of IFN β 
promoter by as much as 67-fold over uninfected cells and 50-fold over DI particle 
infected control 293-pcDNA cells (Fig. 3.10). Additionally, activation of IFNβ promoter 
was not detected in 293-NP cells (expressing only the N and P proteins) infected with DI 
particles (Fig. 3.11). Replication of DI RNA in 293-NPeGFPL cells, but not in 293-
pcDNA control cells or in 293-NP cells could be demonstrated (Fig. 3.11). These results 
suggest that replication of DI RNA, not entry and uncoating of DI RNA or mere 
expression of the viral replication proteins per se potently activates IFNβ promoter.  
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A kinetic analysis of IFN β promoter activation further revealed that indeed replication of 
DI RNA induced activation of IFN β promoter. In 293-pcDNA cells, DI particle infection 
resulted only basal level of IFNβ promoter activity while in 293-pcNPeGFPL cells 
infected with DI particles, IFNβ promoter activity increased with time post-infection 
(Fig. 3.12). The level of DI RNA at 2 hpi (as determined by RT-PCR in our hand) was 
below detection (Fig. lower panel), but a significant increase in IFN β promoter activity 
(7-fold) over similarly infected control cells could be readily seen. As time post-DI 
particle infection increased, IFN β promoter activity also increased, concomitant with 
increased DI RNA replication (Fig. 3.12 lower panel). Since, in cells expressing only the 
viral N and P proteins and infected with DI particles (a condition in which DI RNA 
replication does not occur), activation of IFNβ promoter was not observed, these studies 
demonstrate that IFNβ promoter activation requires DI RNA replication. As mere 
expression of the three replication proteins did not activate IFN β promoter and the fact 
that we could not detect RNP formation with cellular RNAs in the presence of N, PeGFP, 
and L protein (data not shown), these data strengthens our conclusion that only 
replication of DI RNA induces IFN β.     
3.6 DI RNA replication activates ISRE promoter and NFκB promoter 
In contrast to IFNβ promoter, ISRE promoter contains two ISRE elements which 
can be activated by IFN regulatory factor 3 (IRF3), IRF7, or both (Sarkar et al., 2004). 
To elucidate the effect of DI RNA replication upon IRF3-mediated signaling, an ISRE- 
promoter driven luciferase reporter plasmid was used. DI particle infection of 293-
pcDNA control cells led to a meager 1.7-fold increase in luciferase activity over the 
corresponding uninfected cells (Fig. 3.13 panel A).  
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Figure 3.10:  Induction of interferon by replication of DI RNA. Stable cell 293-
NPeGFPL clone # 206 expressing N, PeGFP, and L proteins or 293-pcDNA control cells 
not expressing the viral proteins were co-transfected with 0.4 μg of IFNβ-Luc along with 
10 ng of pRL-TK (renilla luciferase plasmid from Promega, which served as an internal 
control for transfection efficiency). At 24 hours post-transfection, the cells were either 
mock-infected or infected with DI particles. At 16 hours post-infection, the cells were 
lysed in buffer (Promega) and luciferase assay was performed using Dual Luciferase 
assay kit (Promega). Luciferase activities were expressed as relative fold induction over 
uninfected 293-pcDNA control cells after normalizing with renilla luciferase activity. 
Data from three independent experiments is presented as mean±SD. Samples from a 
similar experiment radiolabeled with 
3
H-uridine were also analyzed for replication of DI 
RNA genome as described in legend to Fig. 2A and shown in lower panel of Fig 3A. DI 
RNAs (– and + sense) are identified on the right. 
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Figure 3.11:  Replication of DI genome in cells expressing N-PeGFP and L proteins. 
HEK-293 cells stably expressing N and P proteins or N, PeGFP and L proteins were 
transfected with luciferase reporter plasmids as described in panel A and then infected 
with DI particles. Luciferase activity in the samples were analysed at 12 hours post DI 
particle infection as described in panel A and expressed as fold change over 293-pcDNA 
control cells. Mean±SD from three independent experiments is presented. Parallel set of 
samples were analyzed for DI RNA replication product by RT-PCR (lower panel). As 
control for similar amounts of total RNA being used in the analysis, RT-PCR products 
for ribosomal protein L32 are also shown.  Representative data for DI RNA replication 
and ribosomal protein L32 mRNA quantitation is shown.  
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Figure 3.12:  Kinetics of IFNβ promoter activation.  
Experimental protocol was the same as described in panel B, except that the samples 
were collected at various times (0, 2, and 12 hours for 293-pcDNA cells and 0, 2, 4, 8, 
and 12 hours for 293-NPeGFPL cells) post DI particle infection. Luciferase activity in the 
samples was measured and expressed as fold change over 293-pcDNA control cells.  
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However, DI particle infection of 293-NPeGFPL cells resulted in greater than 200-fold 
induction of luciferase activity over the uninfected 293-NPeGFP cells (Fig. 3.13, panel 
A). Activation of IFN β gene transcription requires co-ordinate action of IRF3, NFκB and 
ATF2/c-jun transcription factors (Wathelet et al., 1998). Nearly 40-fold induction of 
NFκB promoter activity was observed in 293-NPeGFPL cells infected with DI particles 
as compared to similarly infected 293-pcDNA cells (Fig. 3.13 panel B). For a direct 
verification of IFN-stimulated gene expression, we examined expression of interferon 
stimulated gene-56 (ISG56), one of the viral stress-inducible genes that are induced by 
IFNs, dsRNA, and virus infections (Terenzi et al., 2006). Results (Fig. 3.14) showed 
strong induction of ISG56 protein expression in 293-NPeGFPL cells infected with DI 
particles (lane 4), whereas in uninfected 293-NPeGFPL cells and in 293-pcDNA cells 
with or without DI particle infection, ISG56 protein was undetectable. In each of the 
above studies, DI RNA replication products were readily detected (data not shown). 
Taken together, the results suggest that replication of DI RNA in the 293-NPeGFPL cells 
potently activates IFN and IFN-signaling.  
3.7 Discussion 
Current experimental systems to examine negative-strand RNA virus genome 
replication and transcription largely depend on transient expression of the viral proteins, 
which mostly use the recombinant vaccinia virus expressing the T7 RNA polymerase. 
Long- term effects of replication of viral genomes on host cell functions and the effects 
of host cell functions on viral genome replication is difficult to address using these 
systems 
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Figure 3.13:  Activation of ISRE and NFκB promoter by DI particle replication. The 
experiment was conducted as described in Fig. 1.10 but (A) using the ISRE promoter 
driven luciferase gene. (B) using the NFκB promoter driven luciferase gene.  
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Figure 3.14:  Activation of ISG-56 protein by DI RNA replication. For detection of 
endogenous interferon stimulated gene 56 (ISG56), cell lysate was prepared in lysis 
buffer. Equal amount of total protein was separated by SDS-10% PAGE, transferred to 
PVDF membrane and probed with polyclonal rabbit anti-ISG 56 antibody. A non-specific 
band detected with anti-ISG 56 antibody is identified with an asterisk. The level of actin 
in each sample to serve as loading control was analysed after stripping and re-probing the 
same membrane with anti-actin antibody.    
1         2         3        4
ISG 56
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because vaccinia virus causes significant cytopathic effects. Additionally, since infection 
of cells with VSV and many other negative-strand RNA viruses result in cell death, it is 
not possible to study the effects of virus replication on host cell functions in the context 
of virus infection. This study aimed at establishing a replicon system for VSV to further 
our understanding of virus-host interaction. Though the original objective was not 
achieved, the results uncovered several interesting aspects of VSV biology. Successful 
generation of stable cells expressing N, PeGFP and L proteins together suggests that 
these proteins may not play any observable role in VSV-induced cytopathogenesis. The 
cells expressing the VSV replication proteins appear morphologically normal, and grow 
as do the un-transfected 293 cells or the empty vector-transfected control cells. These 
cells had been maintained in culture for at least 60 passages over a 6 months period and 
no loss of viral protein expression or loss of polymerase functions had been detected, 
indicating that these stable cells can maintain functionality of the replication proteins for 
a long time.  
 In a previous study using separate plasmids encoding Sendai virus NP, P, and L 
proteins, it was possible to establish stable cells expressing the viral proteins 
(Willenbrink & Neubert, 1994). These stable helper cell clones supported and maintained 
Sendai virus DI RNA replication for at least 90 days.  In contrast to the above study, this 
study failed to establish a persistent DI genome replication in NPeGFPL cells. Also 
potent activation of IFN signaling was observed in cells replicating the DI genome. VSV 
M protein is the only protein known to provide counter measure against cellular defense 
system (Ahmed & Lyles, 1998; Her et al., 1997).  Failure to counter measure the cellular 
defense mechanisms activated by the replicating DI RNA genome could be the major 
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contributor for loss of DI genome from the cells. Consistent with the notion, induction of 
ISG56 protein in cells replicating the DI genome at 4
th
 passage was observed and in such 
condition, DI replication product was also observed (data not shown).  However, ISG56 
induction was not detected in the cells which are devoid of DI genome during the later 
passages (data not shown). In case of Sendai virus, N, P or L protein might contribute 
towards counteracting IFN system thus persistent DI genome replication could be 
established. For another member of paramyxoviridae, respiratory syncytial virus (RSV), a 
cell line supporting autonomous replication of RSV replicon was recently established 
(Malykhina et al.).  However, these authors deleted only three glycoprotein genes to 
generate the replicon and coding sequences for other viral genes were intact (Malykhina 
et al., 2011). VSV M protein is also involved in significant cytopathic effects (Black & 
Lyles, 1992; Blondel et al., 1990).  In our lab, we had generated a VSV lacking the G 
protein (described in detail in the next chapter). This virus undergoes single round of 
infection in infected cells and cannot undergo budding yet show cytopathic effects similar 
to wild type VSV, thus strengthening the conclusion that M protein greatly contribute for 
the cytopathic effect.  In association with N, P and L proteins, VSV M protein also plays 
a critical role in regulating a balance between virus transcription and replication by 
inhibiting viral transcription (Pal et al., 1985; Ye et al., 1985). Presence of M protein 
might be absolutely necessary to regulate the transcription and replication of VSV 
genome and absence of M protein could be detrimental for virus life cycle. So the failure 
to establish a replicon system is confounded by limitation to remove the matrix protein 
from the genome. A rabies virus without M and G protein has been generated and this 
virus has been used to study the regulation of transcription and replication by M protein 
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(Finke & Conzelmann, 2003).  However, long-term replication of that mutant rabies virus 
has not been shown. So far, a generation VSV without M protein has not been reported. It 
is tempting to speculate that such a virus may not be viable.  
Nevertheless, generation of stable helper cell lines gave us a unique opportunity 
to investigate several aspect of virus life cycle. Using this cell line, it was shown that 
replication of DI RNA activates IFN and IFN- signaling pathways. It has been reported 
previously that snap-back DI (±) particles of VSV activate interferon signaling. 
Furthermore, a preexisting molecule in the snap-back DI genome (presumably double-
stranded RNA structure) has been proposed to be responsible for induction of IFN, as 
heat-inactivation or UV treatment of DI particles did not inhibit interferon induction in 
chick embryo fibroblast and mouse L cells (Marcus & Gaccione, 1989; Sekellick & 
Marcus, 1982) . Contrary to these findings, our results revealed that replication of DI-T 
RNA with a panhandle-type DI genome (Meier et al., 1984) is required for IFNβ 
activation as well as IFN signaling. Mere entry and uncoating of DI particles or 
expression of only the viral replication proteins was not sufficient to induce the IFN β or 
IFN signaling. VSV DI genomes are synthesized in the form of nucleocapsid and possible 
formation of dsRNA structures in infected cells has not been reported. Viral replication 
intermediates such as dsRNA or ssRNAs with triphosphorylated 5‟-ends are sensed by 
both cytoplasmic sensors, e.g. RIG-I, MDA-5, and Nod2 (Barral et al., 2009; Sabbah et 
al., 2009) and endosomal receptors (Toll-like receptors, TLR3, TLR7/8, TLR9) 
(Thompson & Locarnini, 2007). However, the HEK293 cells are deficient in TLRs and 
Nod2. Therefore, in these cells, IFN induction and signaling might be mediated by RIG-I 
and/or MDA-5 through recognition of DI RNA. RIG-I was shown to be involved in 
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detection of rhabdoviruses and paramyxoviruses and subsequent induction of IFN 
response (Hornung et al., 2006; Kato et al., 2006). However, it has been demonstrated 
recently that MDA-5 is also involved in recognition of measles virus (Ikegame et al.) and 
sendai virus DI particles (Yount et al., 2008). Whether the activation of IFNβ and NFκB 
as a result of VSV DI RNA replication involves one or more of these cytoplasmic sensors 
will require further investigation.   
Since infection of cells with VSV and many other negative-strand RNA viruses 
result in cytopathogenesis and cell death, it is not possible to study the long term effects 
of virus replication on host cell functions in the context of virus infection. VSV-M 
protein mutant viruses have been in use to study IFN activation following VSV infection 
(Ahmed et al., 2008; Ahmed et al., 2009; Kato et al., 2006). However, this virus is also 
cytopathic and long term effect of VSV RNA replication cannot be studied using this 
virus. The system established in this study will provide the opportunity to study global 
effects of viral genome replication on host cell functions in the absence of the 
cytopathogenic effects of VSV M and G proteins.  
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CHAPTER IV 
GENOME WIDE RNAi SCREEN IDENTIFIES HOST PROTEINS REQUIRED 
FOR VSV INFECTION 
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4.1 Genome wide siRNA screen  
To identify host proteins modulating VSV infection, a genome wide siRNA 
screen was conducted. Qiagen genome wide siRNA library was used in 384 well micro-
plate format. In this library, four independent siRNAs targeting each gene were divided 
into two pools each containing two siRNAs per well (two siRNAs per well and two wells 
per gene). Thus, this design created a total of 148 plates (Fig. 4.1 A).  HeLa cells were 
used for the screen. Moreover, most of the siRNAs are validated in HeLa cells. These 
cells can also be readily infected with VSV. VSV-eGFP which expresses enhanced green 
fluorescent protein as an extra cistron (Das et al., 2006) was used in a cell based assay. 
The level of eGFP expression can be correlated with VSV gene expression. AllStars non 
targeting control siRNA (Qiagen) and siRNAs targeting to VSV N and L mRNAs 
(Dharmacon) were used as control siRNAs to verify transfection efficiencies. Screen was 
optimized using the control siRNAs. Optimized conditions for the screen were 
determined empirically. Briefly, 3000 HeLa cells were reverse transfected using 
Lipofectamine RNAiMAX. At 52 hrs post transfection, cells were infected with VSV-
eGFP and at 18 hrs post infection fixed and processed for automated image analysis using 
Cellomics ArrayScan VTI. Cell number (Valid Object Count) and a percent infection was 
obtained for each well. Under these conditions, siRNAs targeting to N and L genes 
reproducibly showed less than 2 % infection.  
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Figure 4.1: Genome wide siRNA screen design.  
(A) Genomic library design. In the Qiagen genomic library, each gene is targeted by 4 
independent siRNA duplexes. Two independent siRNAs targeting the same gene were 
plated in each well of a 384 well plate.  This design created a paired plate set (set AB and 
set CD) and each set has 74 assay plates. Set AB and set CD are identical in terms of the 
position of the target genes. (B) Schematic representation of the primary screen. Arrayed 
siRNAs were reverse transfected to HeLa cells in 384 well plate format. After 52 hours 
post transfection, cells were infected with VSV-eGFP. Eighteen hours post infection, 
cells were fixed and processed for automated image analysis.  Percent infection and total 
cell number for each well were measured.   
4 individual siRNAs targeting 
22909 mRNAs  
A B C D
AB set CD set
Two independent 
siRNAs pooled in 
each well 
Two 74 well plate 
sets
A
B
Reverse transfection of HeLa cells 
Gene Knock down for 
52 hours
Infection with VSV-eGFP
18 hour Infection
Fixing, staining and automated 
image acquisition
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4.2 Statistical analysis to obtain primary hit list candidates 
Some of the wells showed significantly reduced cell number after transfection and 
infection. Reduction in cell number could be due to knock-down of critical cellular genes 
required for cell growth and/or could be due to VSV infection.  Samples showing cell 
numbers 800 or less were omitted from further analysis. Thus, a total of 5536 genes were 
discarded (24% of total genes). Sum rank analysis was used to obtain the primary hit list 
candidates. Many ribosomal proteins were identified in this screen. We decided to omit 
the ribosomal genes from the list because of two reasons: (i) ribosome function is 
required for VSV protein synthesis and these are expected to show in the screen (further 
strengthening the robustness of the screen) and (ii) we were interested to identify some 
other unknown genes. So we ran the sum rank analysis after deleting the ribosomal genes 
from the database. A „p value‟ was given to each gene and a hit list was obtained 
(p<0.01).  This list contained 174 genes. Examination of percent infection for these genes 
showed that all these genes had percent infection below 12% where as the percent 
infection of non-targeting control siRNA was approximately 60 % and thus genes in this 
hit list showed approximately five fold inhibitory effects on VSV infection when knocked 
down.  
4.3 Secondary validation screen 
Primary candidates obtained from the genome scale RNAi screens are often 
populated with off target effects. To reduce the false discoveries and off target effects, the 
primary screen was conducted in 2 X 2 formats. This format offered significant 
advantages compared to the pool of four format and a recent report successfully applied  
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Figure 4.2: Schematic of secondary validation screen. Arrayed siRNAs were reverse 
transfected into HeLa cells in 96 well plate format. After 51 hours post transfection, cells 
were infected with VSV-eGFP. Sixteen hours post infection, cells were fixed and 
processed for automated image analysis.  Percent infection and total cell number for each 
well were measured.   
Reverse transfection of HeLa cells 
Dharmacon on target plus pool of 4 
Gene Knock down for 50 
hours
Infection with VSV-eGFP or 
LCMVr3-GFP or HPIV3-GFP
18 hr  or 36 hr infection
Fixing, staining and automated 
image acquisition
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this format to identify genes involved in circadian clock and genes required for Yellow 
fever virus infection (Barrows et al.,2010; Zhang et al., 2009a). This 2 X 2 format 
resulted in high percentage of validation in secondary deconvolution assays (Zhang et al., 
2009a). In our primary screen, the genes identified had at least two independent siRNAs 
showing the same phenotype on VSV infection. In siRNA screens using a pool of four 
siRNAs, if two siRNAs in the subsequent validation screen show the same phenotype, it 
is generally considered to be the true effect of the gene knockdown and not to be due to 
off-target effects (Karlas et al., 2010; Konig et al.,2010; Sharma & Rao, 2009). 
Nevertheless, we took a more conservative approach and decided to use siRNA from a 
different manufacturer for the secondary validation screen rather than deconvoluting the 
siRNA from the primary screen. This approach ameliriorated any bias in siRNA target 
prediction and synthesis of siRNA by a particular manufacturer. So for the secondary 
validation screen, Dharmacon On Target plus pool of four siRNA was used. We had total 
174 genes for the secondary screen. The assay plate format was also changed to 96-well 
format to increase the number of cells transfected and infected and thereby increasing the 
statistical power. A schematic of secondary validation screen is shown in figure 4.2. 
Similar to primary screen, a cell based screen was used for the secondary assay. Percent 
infection and valid object counts were obtained for each well.  The secondary validation 
screen was repeated four times. For statistical analysis, data was normalized to plate wise 
median, and Wilcoxon rank sum test was applied to identify genes inhibiting VSV 
infection after knockdown. Using this method, we were able to identify at least 72 genes 
as required factors for VSV infection, thus yielding a validation rate of 40% from the 
primary list. These genes showed statistically significant difference (p < 0.01) in percent 
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infection compared to NT control wells. Although some of the genes (vATPases) were 
previously known to be involved in VSV infection, majority of genes have not been 
implicated in VSV infection. Table 4.1 represents the list of genes, their known and 
putative functions and their sub-cellular localizations.  
4.4 Identification of host genes required for LCMV and HPIV3  
In recent years, several groups have completed genome wide siRNA screens for 
HIV, HCV and other positive strand RNA viruses. However, there are no such reports for 
negative strand RNA viruses except for Influenza. The negative strand RNA viruses also 
comprises of several medically important pathogens. In order to gain a better 
understanding of virus-host interaction and identify genes and pathways utilized by a 
diverse family of negative strand RNA viruses, the involvement of 174 genes (identified 
in the screen using VSV) was investigated in infection of cells with Human Parainfluenza 
virus 3 (HPIV3) a member of Paramyxoviridae family and Lymphocytic 
choriomeningitis virus (LCMV) a member of Arenaviridae family. These viruses are 
cytoplasmically replicating RNA viruses but belong to different families and have 
different genome organizations. These viruses show common as well as unique strategies 
for entry, uncoating, genome replication, and virus assembly processes in infected cells. 
Therefore, it was with great interest that we examined the involvement of host factors 
identified from the VSV screen in LCMV and HPIV3 infection. For the screen, GFP 
expressing LCMV and HPIV-3 were used (Emonet et al., 2009; Zhang et al., 2005). 
Similar to VSV, for these viruses the screen was conducted in 96-well plate format and 
percent infection and valid object count was obtained for each well. Hit list was identified 
using Wilcoxcson rank sum test. Seventy one and thirty genes were identified as 
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candidates required for LCMV and HPIV respectively. Figure 4.3 A depicts the degree of 
overlap among the three viruses. Twenty five genes were found to be required by all three 
viruses. Among these required factors, VSV and LCMV shared maximum number of 
genes (54) where as VSV and HPIV shared only 27 genes. Genes such as FAAH, 
NUP160, SLC12A9 and SLC43A2 were identified consistently as required factors in 
LCMV infection only. Genes such as GLYATL1 and SLC39A7 were found to be 
required for HPIV-3 infection only. The normalized percent inhibition compared to NT 
siRNA treated wells for 72 genes (positive for VSV) were shown as a color coded map 
and compared to those in LCMV and HPIV infection (Fig. 4.3 B). Majority of the genes, 
when depleted, reduced VSV infection by two fold or more. This screen also identified 
several previously known candidates such as vacuolar ATPases involved in VSV and 
LCMV infection whereas HPIV-3 was insensitive to vATPase depletion. VSV and 
LCMV enter the cells through endocytosis and require the vATPases whereas HPIV 
enters through fusion at the plasma membrane.  These results lent support for the 
robustness of the assay.  
4.5 Bioinformatics analysis 
Over representation of biological functions was analyzed by Panther classification system 
(Mi et al., 2005). Gene ontology biological function enrichment analysis identified 8 
statistically significant functional groups based on hyper geometric p values (Fig. 4.4). 
Biological functions such as vesicle mediated trafficking, intracellular protein transport, 
exocytosis were enriched in the dataset.  We were interested in examining whether other 
viruses such as influenza, HCV, HIV shared these mammalian genes for 
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Gene symbol 
Gene 
ID Description Uniprot function 
Uniprot 
sub- cellular 
location 
ADAL 161823 
Adenosine deaminase-like 
protein 
Putative nucleoside deaminase. May catalyze the 
hydrolytic deamination of adenosine or some similar 
substrate 
Cytoplasm  
ANKRD53 79998 
Ankyrin repeat domain-
containing protein 53   
ARCN1 372 Coatomer subunit delta 
Coatomer complex is required for budding from Golgi 
membranes, and is essential for the retrograde Golgi-
to-ER transport of dilysine-tagged proteins 
Cytoplasm 
and Golgi 
aparatus 
ARF1 375 ADP-ribosylation factor 1 
Involved in protein trafficking among different 
compartments. Modulates vesicle budding and 
uncoating within the Golgi complex. Deactivation 
induces the redistribution of the entire Golgi complex 
to the endoplasmic reticulum, suggesting a crucial role 
in protein trafficking 
Golgi 
membrane, 
cytosol, 
perinuclear 
region of 
cytoplasm, 
plasma 
membrane  
ARHGAP23 57636 
Rho GTPase-activating 
protein 23 
GTPase activator for the Rho-type GTPases by 
converting them to an inactive GDP-bound state  
ATP6AP2 10159 
ATPase H(+)-transporting 
lysosomal accessory protein 
2 
Encodes a component of vacuolar ATPase (V-
ATPase). May mediate renin-dependent cellular 
responses by activating ERK1 and ERK2 
Membrane; 
Single-pass 
type I 
membrane 
protein 
Table 4.1 List of genes identified as required factors for VSV 
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ATP6V0B 533 
ATPase, H+ transporting, 
lysosomal 21kDa, V0  
subunit b  
This gene encodes a component of vacuolar ATPase 
(V-ATPase) 
Membrane 
ATP6V0D1 9114 
V-type proton ATPase 
subunit d 1 
Subunit of the integral membrane V0 complex of 
vacuolar ATPase. Vacuolar ATPase is responsible for 
acidifying a variety of intracellular compartments in 
eukaryotic cells 
Endosome 
membrane 
ATPIF1 93974 
ATPase inhibitor, 
mitochondrial 
Endogenous F1F(o)-ATPase inhibitor limiting ATP 
depletion when the mitochondrial membrane potential 
falls below a threshold 
Mitochondrion  
BBC3 27113 Bcl-2-binding component 3 
Essential mediator of p53-dependent and p53-
independent apoptosis 
Mitochondrion  
BCL2L2 79370 Bcl-2-like protein 2 Promotes cell survival 
Mitochondrial 
membrane 
C14ORF111 51077 
rRNA-processing protein 
FCF1 homolog 
Essential protein involved in pre-rRNA processing and 
40S ribosomal subunit assembly 
Nucleus,  
nucleolus 
C2ORF28 51374 Apoptosis-related protein 3 
May play a critical role in inducing the cell cycle arrest 
via inhibiting CCND1 expression in all-trans-retinoic 
acid (ATRA) signal pathway 
Cell 
membrane; 
Single-pass 
membrane 
protein 
C9ORF96 169436 
Protein kinase-like protein 
SgK071   
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CARD14 79092 
Caspase recruitment domain-
containing protein 14 
Activates NF-kappa-B via BCL10 and IKK. Stimulates 
the phosphorylation of BCL10. 
Cytoplasm  
CDK15 65061 Cyclin-dependent kinase 15 
Serine/threonine-protein kinase involved in the control 
of the eukaryotic cell cycle, whose activity is 
controlled by an associated cyclin 
 
CEACAM7 1087 
Carcinoembryonic antigen-
related cell adhesion 
molecule 7 
 
Cell 
membrane; 
Lipid-anchor,  
GPI-anchor 
COPA 1314 Coatomer subunit alpha 
Coatomer complex is required for budding from Golgi 
membranes, and is essential for the retrograde Golgi-
to-ER transport of dilysine-tagged proteins 
Cytoplasm 
and Golgi 
apparatus 
membrane 
COPB 1315 Coatomer subunit beta 
Coatomer complex is required for budding from Golgi 
membranes, and is essential for the retrograde Golgi-
to-ER transport of dilysine-tagged proteins 
Cytoplasm 
and Golgi 
aparatus 
membrane 
COPB2 9276 Coatomer subunit beta' 
Coatomer complex is required for budding from Golgi 
membranes, and is essential for the retrograde Golgi-
to-ER transport of dilysine-tagged proteins 
Cytoplasm 
and Golgi 
apparatus 
membrane 
COPG 22820 Coatomer subunit gamma 
Coatomer complex is required for budding from Golgi 
membranes, and is essential for the retrograde Golgi-
to-ER transport of dilysine-tagged proteins 
Cytoplasm 
and Golgi 
apparatus 
membrane 
COPZ1 22818 Coatomer subunit zeta-1 
Coatomer complex is required for budding from Golgi 
membranes, and is essential for the retrograde Golgi-
to-ER transport of dilysine-tagged proteins 
Cytoplasm 
and Golgi 
apparatus 
membrane 
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CRMP1 1400 
Collapsin response mediator 
protein 1 
Necessary for signaling by class 3 semaphorins and 
subsequent remodeling of the cytoskeleton. Plays a 
role in axon guidance, invasive growth and cell 
migration 
Cytoplasm 
CUL5 8065 Cullin-5 
Core component of multiple SCF-like ECS (Elongin-
Cullin 2/5-SOCS-box protein) E3 ubiquitin-protein 
ligase complexes, which mediate the ubiquitination 
and subsequent proteasomal degradation of target 
proteins. 
 
DCAF13 25879 
DDB1- and CUL4-associated 
factor 13 
Possible role in ribosomal RNA processing May 
function as a substrate receptor for CUL4-DDB1 E3 
ubiquitin-protein ligase complex 
Nucleus,  
nucleolus 
DCD 117159 Dermcidin 
DCD-1 displays antimicrobial activity thereby limiting 
skin infection by potential pathogens in the first few 
hours after bacterial colonization 
Secreted 
DDX60L 91351 DEAD box protein 60-like 
  
EIF3A 8661 
Eukaryotic translation 
initiation factor 3 subunit A 
Component of the eukaryotic translation initiation 
factor 3 (eIF-3) complex, which is required for several 
steps in the initiation of protein synthesis 
Cytoplasm 
EIF3G 8666 
Eukaryotic translation 
initiation factor 3 subunit G 
Component of the eukaryotic translation initiation 
factor 3 (eIF-3) complex, which is required for several 
steps in the initiation of protein synthesis 
Cytoplasm, 
nucleus 
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EIF3S2 8668 
Eukaryotic translation 
initiation factor 3, subunit 2 
beta, 36kDa 
  
ERN2 10595 
Endoplasmic reticulum-to-
nucleus signaling 2 
Induces translational repression through 28S ribosomal 
RNA cleavage in response to ER stress. Pro-apoptotic. 
Endoplasmic 
reticulum 
membrane, 
single-pass 
type I 
membrane 
protein 
FAM167B 84734 Protein FAM167B 
  
FAU 2197 40S ribosomal protein S30 
This ribosomal protein is synthesized as a C-terminal 
extension protein (CEP) of a ubiquitin-like protein 
Cytosolic 
FBL 2091 
rRNA 2'-O-methyltransferase 
fibrillarin 
Involved in pre-rRNA processing. Utilizes the methyl 
donor S-adenosyl-L-methionine to catalyze the site-
specific 2'-hydroxyl methylation of ribose moieties in 
pre-ribosomal RNA. Site specificity is provided by a 
guide RNA that base pairs with the substrate 
Nucleus,  
nucleolus 
FOXF2 2295 Forkhead box protein F2 
Probable transcription activator for a number of lung-
specific genes. 
Nucleus 
FRS2 10818 
Fibroblast growth factor 
receptor substrate 2 
Adapter protein that links FGR and NGF receptors to 
downstream signaling pathways. Involved in the 
activation of MAP kinases 
Cytoplasmic, 
membrane-
bound 
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GABBR2 9568 
Gamma-aminobutyric acid 
type B receptor subunit 2 
Receptor for GABA. The activity of this receptor is 
mediated by G-proteins that inhibit adenylyl cyclase 
activity, stimulates phospholipase A2, activates 
potassium channels, inactivates voltage-dependent 
calcium-channels and modulates inositol phospholipids 
hydrolysis 
Cell 
membrane 
GBF1 8729 
Golgi-specific brefeldin A-
resistance guanine nucleotide 
exchange factor 1 
Promotes guanine-nucleotide exchange on ARF5. 
Promotes the activation of ARF5 through replacement 
of GDP with GTP 
Golgi 
membrane 
GRM2 2912 
Metabotropic glutamate 
receptor 2 
Receptor for glutamate. The activity of this receptor is 
mediated by a G-protein that inhibits adenylate cyclase 
activity. May mediate suppression of 
neurotransmission or may be involved in 
synaptogenesis or synaptic stabilization 
Cell 
membrane 
H1FOO 132243 Histone H1oo 
May play a key role in the control of gene expression 
during oogenesis and early embryogenesis, presumably 
through the perturbation of chromatin structure. 
Essential for meiotic maturation of germinal vesicle-
stage oocytes 
Cytoplasm, 
Nucleus 
HNRPK 3190 
Heterogeneous nuclear 
ribonucleoprotein K 
One of the major pre-mRNA-binding proteins. Binds 
tenaciously to poly(C) sequences. Likely to play a role 
in the nuclear metabolism of hnRNAs, particularly for 
pre-mRNAs that contain cytidine-rich sequences. Can 
also bind poly(C) single-stranded DNA. 
Cytoplasm, 
nucleus 
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HSPA9B 3313 
Stress-70 protein, 
mitochondrial 
Implicated in the control of cell proliferation and 
cellular aging. May also act as a chaperone. 
Mitochondrion 
IFI35 3430 
Interferon-induced 35 kDa 
protein  
Nucleus 
KCNH4 23415 
Potassium voltage-gated 
channel subfamily H  
member 4 
Pore-forming (alpha) subunit of voltage-gated 
potassium channel. Elicits an outward current, but 
shows no inactivation. Channel properties may be 
modulated by cAMP and subunit assembly. 
Membrane 
LAMC3 10319 Laminin subunit gamma-3 
Binding to cells via a high affinity receptor, laminin is 
thought to mediate the attachment, migration and 
organization of cells into tissues during embryonic 
development 
Secreted 
LYSMD1 388695 
LysM and putative 
peptidoglycan-binding 
domain-containing protein 1 
  
MAT2A 4144 
S-adenosylmethionine 
synthase isoform type-2 
Catalyzes the formation of S-adenosylmethionine from 
methionine and ATP  
NHP2L1 4809 NHP2-like protein 1 
Binds to the 5'-stem-loop of U4 snRNA and may play 
a role in the late stage of spliceosome assembly. The 
protein undergoes a conformational change upon 
RNA-binding 
Nucleus 
NOL5A 10528 Nucleolar protein 56 Required for 60S ribosomal subunit biogenesis. Nucleus 
NRL 4901 
Neural retina-specific leucine 
zipper protein 
Transcription factor which regulates the expression of 
several rod-specific genes, in cluding RHO and 
PDE6B 
Nucleus 
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OR7A10 390892 Olfactory receptor 7A10 Odorant receptor 
Cell 
membrane 
P2RY10 27334 Putative P2Y purinoceptor 10 Putative receptor for purines coupled to G-proteins. 
 
PIWIL3 440822 Piwi-like protein 3 
Acts via the piRNA metabolic process, which mediates 
the repression of transposable elements during meiosis.  
Directly binds piRNAs, a class of 24 to 30 nucleotide 
RNAs that are generated by a Dicer-independent 
mechanism.   
Cytoplasm 
PKMYT1 9088 
Membrane-associated 
tyrosine- and threonine-
specific cdc2-inhibitory 
kinase 
Acts as a negative regulator of entry into mitosis (G2 
to M transition) by phosphorylation of the CDK1 
kinase specifically when CDK1 is complexed to 
cyclins. Mediates phosphorylation of CDK1 
predominantly on 'Thr-14'. Also involved in Golgi 
fragmentation 
Endoplasmic 
reticulum 
membrane, 
Golgi 
membrane 
PPP1R15B 84919 
Protein phosphatase 1 
regulatory subunit 15B 
Maintains low levels of EIF2S1 phosphorylation in 
unstressed cells by promoting its dephosphorylation by 
PP1 
 
PPP5C 5536 
Serine/threonine-protein 
phosphatase 5 
May play a role in the regulation of RNA biogenesis 
and/or mitosis. In vitro, dephosphorylates serine 
residues of skeletal muscle phosphorylase and histone 
H1. 
Nucleus, 
cytoplasm 
PWP2H 5822 
Periodic tryptophan protein 2 
homolog   
RAB5C 5878 Ras-related protein Rab-5C Protein transport. Probably involved in vesicular traffic 
Cell 
membrane, 
lipid anchor, 
RIT2 6014 GTP-binding protein Rit2 Binds and exchanges GTP and GDP 
Cell 
membrane 
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SDF4 51150 
45 kDa calcium-binding 
protein 
May regulate calcium-dependent activities in the 
endoplasmic reticulum lumen or post-ER compartment 
Golgi 
apparatus 
lumen, 
cytoplasm 
SLC46A1 113235 
Proton-coupled folate 
transporter 
Act both as an intestinal proton-coupled high-affinity 
folate transporter and as an intestinal heme transporter 
which mediates heme uptake from the gut lumen into 
duodenal epithelial cells 
 
SLC9A3 6550 
Sodium/hydrogen exchanger 
3 
Involved in pH regulation to eliminate acids generated 
by active metabolism or to counter adverse 
environmental conditions 
Membrane 
SMAD2 4087 
Mothers against 
decapentaplegic homolog 2 
Receptor-regulated SMAD (R-SMAD) that is an 
intracellular signal transducer and transcriptional 
modulator activated by TGF-beta (transforming growth 
factor) and activin type 1 receptor kinases. 
Cytoplasm 
SYVN1 84447 
E3 ubiquitin-protein ligase 
synoviolin 
Acts as an E3 ubiquitin-protein ligase which accepts 
ubiquitin specifically from endoplasmic reticulum-
associated UBC7 E2 ligase and transfers it to 
substrates, promoting their degradation 
Endoplasmic 
reticulum 
membrane 
TAS2R48 259294 
Taste receptor type 2 member 
19 
Receptor that may play a role in the perception of 
bitterness and is gustducin-linked 
Membrane 
TIPIN 54962 
TIMELESS-interacting 
protein 
Required for normal progression of S-phase. Important 
for cell survival after DNA damage or replication 
stress. 
Cytoplasm 
TOX 9760 
Thymocyte selection-
associated high mobility 
group box protein TOX 
May play a role in regulating T-cell development Nucleus 
UQCRC1 7384 
Cytochrome b-c1 complex 
subunit 1, mitochondrial 
A component of the ubiquinol-cytochrome c reductase 
complex (complex III or cytochrome b-c1 complex), 
which is part of the mitochondrial respiratory chain 
Mitochondrion 
inner 
membrane 
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UTP11L 51118 
Probable U3 small nucleolar 
RNA-associated protein 11 
Involved in nucleolar processing of pre-18S ribosomal 
RNA 
Nucleus 
UTP6 55813 
U3 small nucleolar RNA-
associated protein 6 homolog 
Involved in nucleolar processing of pre-18S ribosomal 
RNA 
Nucleus 
WDR46 9277 
WD repeat-containing 
protein 46   
ZNF446 55663 Zinc finger protein 446 May be involved in transcriptional regulation. Nucleus 
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Figure 4.3:  Effect of gene depletion on VSV, LCMV and HPIV3 infection 
A. Ven diagram depicting host factors shared by VSV, LCMV and HPIV.  
B. Relative fold inhibition of infection in siRNA treated wells compared to non-targeting 
siRNA well was calculated. Data represents average values from 4 independent 
experiments for VSV and 3 independent experiments for LCMV and HPIV3. Percent of 
non-targeting control calculated for each of 72 genes was depicted as color coded map. 
Blue represent strong inhibition whereas red represent weak inhibition.  
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 Figure 4.4: Biological process classifications for the identified candidates 
Gene ontology biological process terms significantly overrepresented by the genes in the 
screen were identified using panther classification system. The terms were ordered by the 
number of genes represented in a category. Values in the parenthesis denote number of 
genes and the p values.  
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their infection. We analyzed the candidate genes identified in other human genomewide 
siRNA screens by biological function using Panther database. Gene ontology terms were 
identified for each of these screens and statistical significance was obtained by 
hypergeometric p values. Functions with p values < 0.05 were considered significant. 
Figure 4.5 shows the biological function enriched in VSV dataset and also identifies 
involvement of these gene ontology terms in screens with other viruses. This analysis 
revealed that several biological functions such as exocytosis, vesicle mediated transport 
and intracellular transport are shared by other human pathogens such as influenza, HIV 
and HCV. Some functions such as segment specification and gut mesoderm development 
are uniquely required by VSV.  The limited overlap of identified candidates between 
screens for the same pathogen is a growing concern in the field. The precise reasons for 
this disparity are not known.  Till now there is no such screen for VSV or any other 
cytoplasmic replicating negative strand RNA viruses. Therefore, a direct comparison of 
data is not possible. The replication mechanism for Influenza, HIV and positive strand 
RNA viruses are different from VSV.  However, identification of pathways shared by all 
these viruses implicates evolutionary conserved mechanisms of virus-host interactions.  
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Figure 4.5: Comparison of genome-wide screens between VSV and other viruses 
Candidates genes identified in the VSV screens were compared for the biological 
function with human genome wide screens for HIV, HCV, Influenza and WNV. 
Predicted gene ontology for biological functions was obtained and hypergeometric p 
value was obtained. Results from human genome wide screen for HIV (Brass et al., 2008, 
Zhou et al.2008), HCV (Tai et al., 2009,  Li et al., 2009), Influenza (Konig et al., 2010, 
Karlas et al, 2010, Brass et al., 2009) and WNV (Krishnan et al., 2008) were used for 
classification of biological functions. 
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4.6 Discussion 
In the previous years, considerable advancements have been made in our 
understanding of the roles of VSV proteins in viral genome replication and pathogenicity. 
However, the role of host proteins in VSV infection is poorly understood. During the last 
2-3 years, RNAi technology has been successfully applied to identify factors involved in 
infection of several viruses including Influenza, HIV, HCV, WNV and Dengue virus. 
However, so far there has not been such investigation for any of the nonsegmented 
negative strand RNA viruses. This study describes a genome-wide siRNA screen to 
identify genes required for VSV infection. This approach allowed us to identify factors 
required for VSV infection in an unbiased manner. In the primary screen, we used Qiagen 
siRNA to knockdown genes in HeLa cells. HeLa cells were used because these cells can 
be easily transfected with the siRNA and VSV readily infects these cells. Four 
independent siRNAs were used per gene in a pool of 2 format.  The 2 X 2 pool genomic 
screen design required that at least two independent siRNA generate the same phenotype. 
Thus the 174 genes identified as required factors for VSV infection by sum rank analysis 
from the primary screen showed significant reduction of VSV gene expression when 
knocked down and atleast two independent siRNA show the same phenotype. The off-
target effects are generally associated with hit identification in such genomic screens, 
thus, we used a more robust approach for the validation screen.  Because in the primary 
screen, at least two independent siRNAs produced the same phenotype in VSV infection, 
the likelihood of obtaining the same phenotype is strong had we deconvoluted the 
original Qiagen siRNA pools. Instead, we changed the source of siRNA for the validation 
screen. This approach has two advantages; (i) factors associated with siRNA design and 
manufacturing can be avoided, (ii) change in the source allowed us to test more 
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independent siRNAs targeting one particular gene. Therefore, for the validation screen 
we used Dharmacon “On Tagtet Plus” pool of 4 siRNAs. To provide more statistical 
power, we also changed the plate format to 96 well format and the validation screen was 
done in quadruplicate. In this manner, the 72 genes identified in the secondaty validation 
screen had altogether atleast three independent siRNAs showing the same phenotype (at 
least two siRNAs from the primary screen and at least one siRNA from the validation 
screen). Our primary and secondary validation screens were designed to identify factors 
required at all the stages of VSV infection such as virus entry and uncoating, gene 
expression, and virus budding. This screen also identified genes which were previously 
known to be involved in VSV gene expression such as vATPases further advocating the 
robustness of the screen.  
Although there have been great advancement in the field of RNAi technology, the 
output from a genome-wide screen requires stringent validation. Several laboratories 
have made considerable efforts to identify host factors for other pathogenic human 
viruses such as HIV, Influenza and HCV. However, the limited number of overlapping 
genes identified from these screens for the same virus is a concern. Several factors 
potentially contribute to the outcome of such genomic screens e.g. types of cell line, 
types of siRNA, different strain of virus, type of statistical analysis performed etc 
(Barrows et al.,2010; Goff, 2008; Watanabe et al., 2010). Several other technical 
limitations of this approach also can not be ignored. For example, the stability of mRNA 
and knockdown efficiency for each gene is different. It is not possible to standardize the 
knockdown efficiency for each and every gene in the genome-scale screen.  Also if the 
function of a particular gene is redundant with other genes, it may not be identified 
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because this approach knocks down a single gene at a time. Depletion of critical genes 
shows toxic effects on the host and these genes are also omitted from the analysis. 
Despite several limitations, the genome-wide siRNA screen provides an unparalleled 
advantage to probe for function of unknown genes not only in viral infection, but also in 
other biological conditions. Detailed investigation of functions of these genes will allow 
us to find novel drug targets against viral diseases. Also several drugs targeting host 
proteins are in clinical trials for influenza and HIV (Coley et al., 2009; Hayden, 2009; 
Ludwig, 2009; Moss et al., 2010).  In our screen, because of the more stringent approach, 
the possibility of false positive genes in our hit list may be lower. Moreover, the high 
stringency of our hit identification might have compromised our ability to identify 
additional genes required for VSV infection.  
We also tested the involvement of these genes in LCMV and HPIV3 infection. 
LCMV and HPIV3 belong to Arenaviridae and Paramyxoviridae family respectively. 
These viruses also contain negative strand RNA genome and replicate in the cytoplasm. 
There is also no comprehensive analysis of virus-host interaction for these viruses. 
Results obtained with VSV can be extrapolated to other negative strand RNA viruses. We 
show here that many of the genes identified as required factor for VSV are also involved 
in LCMV and HPIV3 infection. For example, COPI is required for VSV as well as for 
LCMV and HPIV3, further underscoring the notion of using VSV as a model virus. 
Genes involved in endosomal function such as vATPases are required for VSV and 
LCMV entry, but not for HPIV3 entry.  In the secondary validation screen we also 
positively identified vATPase subunits for VSV and LCMV but not for HPIV3. Some 
genes are uniquely required by VSV such as BCL2L2, C2ORF28 and IFI35. The detailed 
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mechanism by which these genes impact VSV infection is not known. Some genes for 
example C11ORF42 are required by LCMV only where as GLYATL1 is required only 
by HPIV3. These results suggest that though these viruses use a subset of genes for their 
infection, there may be some mechanisms unique to each family of viruses.  
Biological process classification revealed that the genes required for VSV 
infection were enriched in several functional categories such as exocytosis, vesicle 
mediated transport, protein transport among others. Many of these processes are uniquely 
identified for VSV, whereas some of the functions are shared by other virus families such 
as Influenza, HIV and HCV emphasizing the evolutionarily conserved as well as unique 
adaption displayed by these viruses.   
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CHAPTER V 
HOST COATOMER PROTEIN COMPLEX I (COPI) FUNCTION IS REQUIRED 
FOR VSV RNA SYNTHESIS 
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5.1 COPI is required for early stage of VSV infection in HeLa cells 
Network and biological function analysis of the validated candidates identified 
vesicle trafficking pathway as the top scoring pathway. Among these genes, there are six 
sub units of coatomer 1 (COPI) vesicular transport complex. The well characterized 
function of COPI is the retrograde transport of luminal and membrane proteins from 
Golgi to ER (Beck et al., 2009; Lee et al., 2004). COPI complex also plays a role in 
steady state distribution of proteins in the Golgi thereby maintaining anterograde 
transport (Tu et al., 2008). We focused on COPI pathway because knockdown of all the 
COPI sub units except COPE resulted in strong inhibition of VSV infection. Further 
examination showed a concomitant decrease in VSV gene expression when the COPI sub 
units were depleted by siRNA (Fig. 5.1 A). Six out of seven COPI sub-units (except 
COPE) were found to be required for VSV infection as determined by eGFP expression 
in a multi round infection (Fig. 5.1A). Similar results were obtained when we examined 
VSV M protein expression (data not shown).There was also a more than 50 fold 
reduction of infectious VSV production after depletion of COPI (data not shown). VSV G 
protein is processed through early secretory pathway and VSV assembly is affected if this 
process is disturbed (Orci et al., 1997; Ostermann et al., 1993). So, COPI depletion might 
have affected VSV G protein processing and consequently affected infectious virus 
production. Nevertheless, COPI depletion had a strong effect on VSV infection. 
Therefore, we were interested to examine if COPI plays a role in any other stage of VSV 
infection. To this end, we examined if the COPI components play a role in entry and 
uncoating as well as gene expression of VSV.  The effect of depletion of COPI sub units 
on VSV gene expression was examined at 4 hrs post infection.  Four hrs of infection is 
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considered as early stage of VSV infection and at this time point VSV gene expression 
can be readily detected but there is minimal virus budding and re-infection. Depletion of 
all the COPI subunits except COPE reduced VSV protein expression by 5-10 fold as 
evidenced by western blot analysis of M protein (Fig 5.1B).  Decrease in protein 
expression could be due to reduced translation of protein from the mRNA or other steps 
prior to translation.  To determine if there is any difference in RNA production, we 
examined VSV mRNA, genomic RNA and antigenomic RNA (replication product) after 
COPI knockdown. We found reduced level of transcripts as well as antigenome and 
genome RNA (Fig. 5.1C and data not shown).  These results suggest that COPI functions 
at the level of VSV RNA synthesis by facilitating transcription and/or replication from 
the genome or enhancing the stability of RNA. Because depletion of multiple COPI sub 
units produced same phenotype on VSV infection, we considered that the effects of 
siRNAs are true effects due to protein depletion. Moreover, if two independent siRNAs 
produce the same phenotype, then the phenotype is generally considered on target. We 
verified protein expression of endogenous COPZ1 and COPB1 after gene knock-down by 
individual siRNA transfection.  Figure 5.2A shows that two siRNA duplexes strongly 
reduced COPZ1 protein expression (> 90% inhibition of protein) whereas one siRNA 
duplex partially reduced COPZ1 expression. Three siRNA duplexes also significantly 
reduced COPB1 protein. When VSV M protein expression was examined under these 
conditions, we found that the more the gene is knocked down, the stronger is the 
inhibition of VSV M protein expression. To verify if other COPI subunits also affect 
similarly, we deconvoluted the pool of 4 siRNA and found that for each COPI sub units 
(except COPE), knock-down by at least two independent siRNAs  
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Figure 5. 1: Effects of COPI depletion on VSV protein and RNA synthesis  
(A) HeLa cells were transfected with pool of four siRNAs targeting each of seven COPI 
subunits, and then infected with VSV-eGFP for 16 hours. VSV gene expression was 
assessed by western blot analysis for eGFP. (B) HeLa cells were transfected as described 
in (A) but infected with VSV-eGFP for 4 hours. VSV M protein expression was 
examined by immunoblotting. Lower panel shows relative level of M protein expression 
normalized to non-targeting control sample. Data represent mean ± SD from three 
independent experiments. (C) Quantitaive real time PCR measurement of VSV P RNA 
and VSV anti-genomic RNA. Values were obtained from duplicate measurements of each 
sample from two independent experiments and presented as mean ± SEM after 
normalizing to NT control. 
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 Figure 5.2:  Depletion of COPI sub-units affects VSV gene expression  
HeLa cells were transfected with individual siRNA duplex targeting COPZ1 (A) and 
COPB1 (B) subunits, then infected with VSV-eGFP for 4 hours. VSV gene expression 
was assessed by western blot analysis for M protein. (B)  HeLa cells were transfected 
with individual siRNA duplex targeting each of seven COPI sub units, then infected with 
VSV-eGFP for 4 hours. VSV gene expression was assessed by western blot analysis for 
M protein. Average relative fold expression of M protein normalized to NT control wells 
was presented from three independent experiments.  
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resulted in reduced VSV gene expression (Fig 5.2 B).  It is of note that depletion of 
ARCN1 and COPA by all four siRNAs strongly reduced VSV gene expression. These 
results argues strongly infavor of involvement of COPI function in VSV gene expression. 
To further confirm the role COPI in VSV infection, we disrupted the function of COPI 
using a pharmacological agent 1, 3-cyclohexanebis methylamine (CBM), which has been 
shown previously to inhibit COPI function (Hu et al., 1999; Zhang et al., 2009b). Similar 
to siRNA results, we also observed that inhibition of COPI function using CBM 
affectedVSV M protein synthesis at early stage of viral infection (Fig. 5.3 A). CBM 
treatment not only reduced VSV protein expression but also reduced VSV mRNA and 
anti genome levels at 3 hrs post infection (Fig. 5.3 B).  When CBM was treated at 1 hr 
after VSV infection, more than 10 fold inhibition of VSV RNA expression was observed. 
This result suggests that COPI predominantly functions to regulate VSV RNA synthesis 
at the level of transcription and/or replication rather than affecting the primary 
transcription of input genomic RNA. The above experiment cannot completely exclude 
the possibility that COPI is involved in primary transcription of VSV. Collectively the 
results suggest involvement of COPI in early stage of VSV infection primarily regulating 
VSV RNA synthesis.  
5.2 COPI is required for early stage of LCMV and HPIV3 infection  
Our validation screen also identified involvement of COPI in arenavirus (LCMV) 
and paramyxovirus (HPIV3) infection. Similar to VSV, these viruses also replicate in the 
cytoplasm. Because COPI was found to be required for early stage of VSV infection, we 
examined the role of COPI in early stage of LCMV and HPIV infection. We knocked 
down COPI function by siRNA and subsequently infected with LCMV and HPIV3. Cell 
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lysates were collected at 8 hr post infection for LCMV and 14 hr post infection for 
HPIV3. As a measure of replication, level of GFP protein was examined by western blot 
analysis. Similar to VSV, depletion of the 6 sub-units of COPI also significantly affected 
LCMV and HPIV3 gene expression at early stage of infection (Fig. 5.4). Taken together, 
COPI is required not only for VSV RNA synthesis but also is required early in infection 
in case of other cytoplasmic replicating negative-strand RNA viruses such as LCMV and 
HPIV3.  
5.3 COPI functions to regulate VSV RNA synthesis 
Previous reports have identified a role for COPI in VSV G protein processing 
(Orci et al., 1997; Ostermann et al., 1993). Also βCOP is involved in endosomal 
transport (Aniento et al., 1996; Whitney et al., 1995) and VSV entry is mediated by 
endosomal acidification (Le Blanc et al., 2005). COPI has multiple functions inside the 
cell and might have effects on multiple stages of VSV infection. Therefore, we wanted to 
examine in detail how COPI is modulating VSV infection. To rule out the possibility that 
the effect of COPI in early stage of VSV infection is dependent on its function to process 
G protein, we used a recombinant VSV without encoding a G protein (VSV∆G) (Fig. 5.5 
A). Infectious viruses were generated by supplementing G protein by exogenous 
expression during infection. VSV∆G virus can undergo single round of infection but can 
not bud and re-infect new cells as the viral genome lacks G gene. Reduction inVSV gene 
expression was also observed when the COPI-depleted cells were infected with VSV∆G 
(Fig. 5.5 B). These results further strengthens the conclusion that COPI plays a role in an 
early stage of VSV infection possibly by facilitating entry and/or gene expression of  
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Figure  5.3:  Inhibition of VSV gene expression by CBM 
(A) HeLa cells were infected with VSV-eGFP at 0.5 MOI. After 1 hr of infection, cells 
were washed and CBM was added at the indicated concentrations. Cell lysate was 
prepared at 4 hours post infection and immunoblot was performed for M protein. (B) 
HeLa cells were infected with VSV-eGFP. At 1 hr post infection cells were washed and 
treated with CBM. At 4 hours post infection, RNA was extracted and quantitative RT 
PCR was performed for VSV P mRNA and anti-genome. Value represents mean ± SEM 
of duplicate measurements from two independent experiments.  
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Figure 5. 4:   COPI silencing decreases gene expression of LCMV and HPIV3 
(A) HeLa cells were transfected with pool of 4 siRNAs against the indicated COPI sub 
units and 42 hours post transfection, infected with LCMV for 6 hours. Level of eGFP was 
detected by western blot.  (B) HeLa cells were transfected with siRNAs against the 
indicated COPI subunits and then infected with HPIV for 14 hours. Level of GFP was 
detected by western blot.  
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VSV. To further dissect the role of COPI in VSV entry, uncoating or VSV gene 
expression; we prepared nucleocapsids from VSV virions and transfected these 
nucleocapsids to COPI-depleted cells. Nucleocapsids are functional units for VSV gene 
expression and can initiate gene expression after being delivered into the cells. The 
transfection of nucleocapsids also bypasses the endosome mediated entry and uncoating 
steps of VSV. There was a 2-3 fold reduction of VSV gene expression from the 
nucleocapsids when COPI function was depleted as compared to NT siRNA transfected 
cells (Fig. 5.5 C). These results suggest a role of COPI in VSV RNA synthesis. However, 
because the transfection of nucleocapsids bypasses the entry and uncoating steps, our 
results cannot exclude a role of COPI in VSV entry and uncoating. Furthermore, when 
VSV infected cells were treated with CBM 1 hr post infection, strong inhibition of VSV 
protein synthesis and RNA synthesis was observed (Fig. 5.3). We and others have also 
shown that VSV entry and uncoating is rapid and it takes place within 30 minutes to 1hr 
after virus adsorption (Das et al., 2009; Johannsdottir et al., 2009). To further verify that 
VSV entry and uncoating is rapid and occurs within 1 hour of infection, we used 
Bafilomycin A1, an inhibitor of vATPases and thereby block endosomal mediated VSV 
entry (Le Blanc et al., 2005). Pre treatment of cells (30 minutes before infection) with 
Bafilomycin A1 blocked VSV infection completely whereas VSV infection is insensitive 
to this drug when treated simultaneously with infection or 1 hour post infection 
suggesting that VSV entry and uncoating is rapid. CBM treatment 1 hr post infection and 
subsequent inhibition of VSV gene expression suggest a role of COPI in VSV RNA 
synthesis. Collectively these results suggest that COPI is required for VSV gene  
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Figure 5.5:  COPI silencing affects VSV gene expression independent of VSV entry 
and budding  
(A) Schematic representation of VSV-PeGFP∆G virus. (B) HeLa cells were transfected 
with the indicated siRNAs, then infected with VSV PeGFP ∆G virus. At 5 hr post 
infection, cells were harvested and M protein expression was assessed by 
immunoblotting. Lower panel shows relative level of M protein expression from three 
independent experiments.  (C) VSV nucleocapsids prepared from infectious viruses were 
transfected to cells depleted of COPZ1 and ARCN1. At 6 hrs post nucleocapsid 
transfection, M protein expression was examined by western blot analysis. Lower panel 
shows relative level of M protein expression from three independent experiments. 
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expression and this function of COPI is independent of effect of COPI on G protein 
processing or virus entry through endosome.  
5.4 ARF1 mediated COPI assembly is required for VSV and LCMV but not for 
HPIV3 gene expression   
COPI assembly on the Golgi membrane requires activation of ARF1 (Hsu et al., 2009; 
Hsu & Yang, 2009; Lippincott-Schwartz & Liu, 2006). Upon activation, ARF1 recruits a 
pre-formed COPI complex from the cytoplasm to the Golgi membrane. Because ARF1 is 
the immediate upstream effector of COPI, we were interested to examine involvement of 
the ARF1 in VSV infection. We knocked down ARF1 by siRNA, infected with VSV and 
analyzed VSV M protein expression. VSV protein expression was reduced by 40% as 
examined by western blot analysis (Fig.5.6 A). Under this knock-down condition using 
the siRNA available to us, ARF1 protein level was also decreased by approximately 50% 
and this correlated with moderate reduction of VSV protein expression (60% of NT 
control).  To re-confirm the role of ARF1 in VSV gene expression, we transfected HeLa 
cells with a dominant negative mutant of ARF1 [ARF1 T31N, (Peters et al., 1995)] and 
examined VSV gene expression. Similar to ARF1 knock-down, moderate inhibition of 
VSV gene expression was observed after disrupting ARF1 function by expression of the 
dominant negative ARF1. Further evidence for the involvement of ARF1 in early stage of 
VSV infection came from experiments with VSV-∆G virus. Depletion of ARF1 also 
affected gene expression of VSV-∆G virus suggesting a role for ARF1 mediated COPI 
assembly on VSV gene expression rather than G protein processing (data not shown). 
Similar to COPI knockdown, ARF1 depletion also affected VSV mRNA level as well as 
genome replication (Fig. 5.6 C). When we examined the role of ARF1 in LCMV and  
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Figure 5. 6:  ARF1 is required for VSV gene expression 
(A) HeLa cells were treated with the pooled siRNAs against ARF1. At 72 hrs post 
transfection, cells were infected with VSV- eGFP at 0.05 MOI. Levels of M protein and 
ARF1 expression were examined at 6 hrs post infection. Values represent mean ± SD 
from three independent experiments. (B) HeLa cells were transfected with the plasmids 
expressing ARF1wt or ARF1T31N. Twenty four hrs post transfection, cells were infected 
with VSV-eGFP for 4 hrs. Levels of M protein and ARF1 expression were examined by 
western blot.  (C) Quantitative real time PCR for VSV P mRNA and antigenome after 
ARF1 depletion. Values were obtained from duplicate measurements of each sample 
from two independent experiments and presented as mean ± SEM after normalizing to 
NT control.  (D) HeLa cells were transfected with pooled siRNA against ARF1 and then 
infected with LCMV for 6 hrs. Level of eGFP expression was examined by western blot 
analysis. (E) Renilla reniformis GFP expression after HPIV infection was assessed in 
cells depleted of ARF1. 
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HPIV-3 gene expression, we found that ARF1 depletion affected LCMV gene expression 
by 50-60% of that of NT control cells where as HPIV3 gene expression appeared to be 
independent of ARF1 function (Fig. 5.6 D and 5.6 E).  
5.5 GBF1, the Guanine Nucleotide Exchange Factor (GEF) for ARF1 is required for 
VSV, LCMV and HPIV3 infection 
ARF1 is post translationally modified by myristoylation at its amino terminus. In 
the GDP bound (inactive) form, the myristoylated motif is sequestered but in GTP bound 
(active) form this motif is exposed. This myristoylated motif is required for membrane  
targeting of ARF1 (Hsu & Yang, 2009). GBF1 is the guanine nucleotide exchange factor 
for ARF1 and GBF1 maintains COPI assembly on the Golgi membrane through ARF1 
activation (Garcia-Mata et al., 2003; Kawamoto et al., 2002). Because of the crucial role 
of GBF1 in COPI pathway, we investigated involvement of GBF1 in VSV gene 
expression. We silenced GBF1 by siRNA and then infected with VSV. Treatment with 
siRNA reduced endogenous GBF1 protein level by 90-95 % (Fig 5.7 A). When GBF1 
was knocked down, a 2.5 fold reduction in VSV protein synthesis was observed (Fig. 5. 7 
A). Additionally a concomitant 2-2.5 fold reduction of VSV mRNA and anti-genome 
level were observed following GBF1 silencing (Fig 5.7 B). Taken together, these results 
suggest that VSV gene expression critically depends on GBF1 functions.  
 Furthermore, we used pharmacological inhibitors of GBF1 to probe for the role of 
GBF1 in VSV gene expression. To this end, we used brefeldin A (BFA), Golgicide A 
(GCA) and Tyrphostin AG1478 (AG1478) to inhibit function of GBF1. BFA is a well 
studied pharmacological inhibitor of GBF1, Brefeldin Inhibited Guanine nucleotide 
exchange factor -1 and -2 (BIG1 and BIG2) (Peyroche et al., 1999) 
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Figure 5.7:  GBF1 controls VSV RNA synthesis 
(A) HeLa cells were transfected with pooled siRNAs against GBF1.  At 72 hours post 
transfection, cells were infected with VSV- eGFP for 4 hours. Levels of M protein and 
GBF1 were examined by western blot. Lower panel shows relative level of M protein 
expression from 3 independent experiments. (B) HeLa cells were transfected with GBF1 
siRNA for 72 hrs, then infected with VSV-eGFP for 3 hrs. Quantitative real time PCR 
was performed for VSV P mRNA and anti-genome. Values represent mean ± SEM from 
duplicate measurements from two independent experiments.  
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whereas, GCA and AG1478 were recently identified and characterized as being more 
specific inhibitors of GBF1 (Pan et al., 2008; Saenz et al., 2009). Similar to siRNA 
mediated depletion of GBF1, VSV protein synthesis (Fig. 5.8 A) and RNA synthesis 
(Fig. 5.8 B) were also sensitive to BFA, GCA and AG1478 treatment.  All the three drugs 
decreased VSV protein level and RNA level by 2-3 fold (Fig. 5.8). To exclude the 
possibility that the effects of these drugs on VSV gene expression were nonspecific due 
to unknown off- target effects rather than specific inhibition of GBF1 function, we used 
Madin Darby canine kidney (MDCK) cells. Dog genome has a naturally occurring 
mutation (M832L) in sec7 domain of GBF1and therefore MDCK cells are resistant to 
BFA, GCA and AG1478 (Lanke et al., 2009; Pan et al., 2008; Saenz et al., 2009; 
Verheije et al., 2008). However, in these cells other Guanine nucleotide exchange factors 
regulating trans-Golgi network functions are sensitive to BFA action (Saenz et al., 2009; 
Wagner et al., 1994). When MDCK cells were infected with VSV and then treated with 
the GBF1 inhibitory drugs, no effect on VSV gene expression was observed even at 
higher concentrations of BFA, GCA and AG1478 (Fig. 5.9 A). In another approach, we 
used BER40 cells. BER40 cell line is a derivative of Vero cell and has a mutation 
(A795E) in GBF1 (Belov et al., 2008) which confers resistance to BFA in the BER40 cell 
line. A 2-fold suppression of VSV gene expression was observed in Vero cells after BFA 
treatment whereas in Ber40 cells VSV gene expression was insensitive to the effect of 
BFA (Fig. 5.9 B). To further provide support for this result that these pharmacological 
inhibitors indeed affected VSV gene expression, time-course experiment was performed. 
In this context, BFA, GCA and AG1478 were added at every 1 hr interval to the cells 
before or following VSV infection and the level of VSV M protein expression 
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Figure 5. 8:  VSV RNA synthesis is sensitive to GBF1 inhibitors 
(A) HeLa cells were infected with one MOI of VSV-eGFP and at 1 hr post infection, 
cells were treated with indicated concentrations of the drugs. Cell lysate prepared at 4 hr 
post infection and M protein expression was assessed by immunoblotting. Lower panel 
shows relative levels of M protein expression from 3 independent experiments. Values 
represent mean ± SD.  (B) HeLa cells were infected with VSV-eGFP and 1 hpi treated 
with BFA (2μg/ml), GCA (10μM) and AG1478 (30μM) for 2 hr. Fold change in P 
mRNA and anti-genome was examined by quantitative RT PCR. Values represent mean 
± SEM from duplicate reactions from two independent experiments.  
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Figure 5.9.  GBF1 is the GEF required for VSV RNA synthesis 
(A) MDCK cells were infected with VSV-eGFP. At 1 hr post-infection cells were treated 
with the indicated concentrations of the drugs. M protein expression was examined by 
immunoblotting at 4 hrs post infection. Lower panel shows relative levels of M gene 
expression from three independent experiments. Values represent mean ± SD. (B) BER 
40 and vero cells were infected with VSV-eGFP. After 1 hr, cells were treated with BFA 
at indicated concentrations. M protein expression was analyzed by western blot analysis.  
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 was determined by immunoblotting (Fig. 5.10). Results showed that VSV M protein 
synthesis was affected when the drugs were added upto 3 hours post infection suggesting 
that VSV RNA synthesis requires GBF1 activity. Experiments with VSV-∆G virus and 
nucleocapsids transfection also showed that GBF1 is required for VSV gene expression 
(data not shown). Collectively, the data unequivocally suggest that GBF1 function is 
required for VSV RNA synthesis.   
 We next examined the requirement of GBF1 in LCMV and HPIV 3 gene 
expression. For this, control or GBF1 depleted cells were challenged with LCMV and 
HPIV-3 and level of GFP expression was examined by western blot analysis. Depletion 
of GBF1 reduced gene expression from both LCMV and HPIV-3 by more than 10 fold 
(Fig. 5.11A and 5.11 B). Similar to the results obtained with siRNA treatment, we 
observed that LCMV and HPIV-3 gene expression were also sensitive to 
pharmacological inhibitors of GBF1 (Fig 5. 11 C and 5.11 D).  Thus from the studies 
reported here, we conclude that GBF1-ARF1-COPI mediated pathway regulates gene 
expression of diverse families of cytoplasmic replicating RNA viruses  
5.6 GBF1 and COPI are not part of VSV replication complex 
Many positive strand RNA viruses re-organize host intracellular membranes and 
utilize them as sites of their genome replication (Hsu et al.,2010). Because of the critical 
role of ARF1, GBF1 and COPI in formation of replication complexes for positive-strand 
RNA viruses, we wanted to investigate if these factors play similar roles in VSV 
infection. We examined sub-cellular localization patterns of endogenous βCOP and 
GBF1 in VSV infected cells. In uninfected cells, βCOP was predominantly localized to a  
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Figure 5.10: GBF1 affects a post entry stage of VSV infection  
HeLa cells were infected with VSV-eGFP and these cells were treated with Brefeldin A, 
Golgicide A or AG1478 at the indicated time points pre or post infection. M protein 
expression was analyzed by western blot analysis at 4 hours post-infection.  
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Figure 5.11:  Requirement of GBF1 for LCMV and HPIV gene expression 
(A) HeLa cells were transfected with GBF1 siRNA and subsequently infected with 
LCMV for 6 hrs. LCMV gene expression was measured by immunoblotting of eGFP.  
(B)HeLa cells were infected with HPIV3 after depleting GBF1. HPIV gene expression 
was assessed by western blot for GFP. (C) HeLa cells were infected with LCMV. At 1 
hour post-infection, cells were treated with indicated concentrations of the drugs for 6 
hours. LCMV gene expression was assessed by western blot examination of eGFP. (D) 
HeLa cells were infected with HPIV3 and 1 hr post-infection treated with indicated 
concentrations of the drugs. HPIV3 gene expression was assessed by western blot for 
GFP.  
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perinuclear site and co-localized to Golgi apparatus (Fig. 5.12). In VSV infected cells the 
localization of βCOP was not altered significantly. A previous report from our lab as well 
as others have shown that VSV replication occurs throughout the cytoplasm and the 
punctuate structures (marked by PeGFP) are the sites for genome replication those also 
contain viral N, L proteins as well as viral RNA (Das et al., 2006). In VSV-infected cells, 
βCOP staining did not absolutely co-localize with VSV replication sites (Fig. 5.12). 
However, punctate structures marked with PeGFP were found in close proximity to 
βCOP. Similar results were also obtained when we examined distribution of GBF1 and 
ARF1 (Fig 5.12 and data not shown). These results suggest that although GBF1 and 
ARF1 mediated COPI activation is required for VSV infection; these proteins may not be 
components of VSV replication complex rather they participate indirectly in modulating 
VSV infection.  
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Figure 5.12:  GBF1 and COPI do not co-localize with VSV replication complex 
HeLa cells were mock-infected or infected with VSV-PeGFP. At 3 hours post infection, 
cells were fixed and stained with endogenous COPB1 (A) or GBF1 (B). Images were 
captured in Laser scanning confocal microscope. All fluorescence images were merged Z 
stacks of 0.5μM thickness.  
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 5.7 Discussion 
This screen identified involvement of COPI complex in VSV gene expression. 
COPI complex was originally identified 25 years ago (Malhotra et al., 1989; Orci et al., 
1986). This complex consists of seven subunits such as α, β, β‟, δ, ε, γ and δ (Hsu et al., 
2009). COPI complex has been shown to mediate transport of cellular proteins and cargo 
from the Golgi to the endoplasmic reticulum as well as intra Golgi transport (Beck et al., 
2009; Orci et al., 1997; Rabouille & Klumperman, 2005). ER resident membrane protein 
cargo can be retrieved back to ER from Golgi by interaction with COPI (Letourneur et 
al., 1994). Recent evidences also suggest a role of COPI in conjunction with COPII in the 
ER to Golgi transport of proteins (Scales et al., 1997). VSV-G protein has been used 
widely as cargo to probe anterograde transport mechanisms. Depletion of COPI perturbs 
the steady state distribution of the Golgi enzymes  (Tu et al., 2008) and in turns inhibits 
transport of  VSV G protein to the plasma membrane for budding. However, we observed 
reduction of VSV gene expression at early stage of infection in cells depleted of COPI. 
Similar effect was also observed when we used a recombinant VSV without G protein. 
These results suggest a role of COPI in early stage of VSV infection and the effect is 
independent of VSV G protein processing and infectious virus production. VSV infection 
involves entry of virus particles through endosomal compartments and subsequent release 
of nucleocapsids to cytoplasm. COPI sub units such as β COP was shown to be present 
on endosomes suggesting involvement of a subsets of COPI vesicles in regulation of 
endosome function (Aniento et al., 1996; Whitney et al., 1995).  The effect of COPI 
depletion on early stage of VSV infection could be due to blockage of VSV entry and/or 
RNA synthesis. Further verification of the role of COPI in VSV gene expression came 
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from nucleocapsid transfection experiments. Nucleocapsids transfection bypasses the 
endosomal entry steps and thus they are delivered directly to the cytoplasm. Moreover, 
results from the drug (CBM, BFA, GCA and AG1478) treatment studies further 
strengthen the conclusion that COPI function is required for VSV gene expression. 
Furthermore, treatment of HeLa cells with 2 μM Bafilomycin A1 30 minutes before 
infection completely blocked VSV infection. However, treatment of Bafilomycin A1 
during infection or 1 hour after infection did not exert its inhibitory effect on VSV RNA 
synthesis. These results confirm that VSV entry and uncoating is rapid, and the effect we 
observed with CBM, BFA, GCA and AG1478 on VSV infection is in fact due to 
interference with VSV RNA synthesis.   
 We did not find components of COPII complex either in the primary screen or in 
the validation screen as required factors in VSV infection. Depletion of one of the COPII 
subunits resulted in statistically insignificant reduction of VSV infection. VSV G protein 
transport is dependent on COPII function (Rowe et al., 1996). The failure to identify 
COPII components as required factors could be due to improper knockdown or other 
compensatory mechanisms. However, COPI subunits emerged stongly in the primary 
screen as well as in the validation screen. The requirement of COPI for genome 
replication has been well-documented for positive strand RNA viruses such as poliovirus, 
HCV and Drosophila C virus  (Cherry et al., 2006; Maynell et al., 1992; Tai et al., 2009).  
The studies presented here revealed the requirement of COPI for gene expression of 
negative-strand RNA viruses further providing evidence for critical role of secretory 
pathway in virus infection.  Not only COPI, but also ARF1 and GBF1 were also found to 
be required for VSV RNA synthesis.  All positive strand RNA viruses replicate in close 
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association with membranous complexes (Ahlquist et al., 2003; Salonen et al., 2005). 
Several positive strand RNA viruses such as polio virus, HCV, CVB3 modulate the 
activities of ARF1, GBF1 and COPI for formation of the intracellular sites of replication 
(Belov et al., 2008; Goueslain et al.; Hsu et al.,2010; Matto et al.; Verheije et al., 2008). 
However, the nature of replication organelles for cytoplasmically replicating RNA 
viruses is not known. It has been demonstrated in earlier reports that VSV genome 
replication occurs throughout the cytoplasm (Das et al., 2006; Heinrich et al., 2010). In 
this study, we did not observe co-localization of VSV replication proteins such as P, N 
and L with ARF1, GBF1 or COPI suggesting that these cellular proteins may not be 
directly involved with the VSV replication complex formation.  Moreover, localization of 
endogenous ARF1, GBF1 and COPI was not altered in VSV infected cells, as compared 
to uninfected cells. Several cellular signaling pathways emanate from GBF1/ARF1/COPI 
pathway including phophotidyl ionositol pathway, actin cytoskeleton organization and 
lipid droplet formation (Donaldson, 2005; Guo et al., 2008; Myers & Casanova, 2008).  It 
is possible that the downstream signaling pathway is affected when the COPI pathway is 
perturbed and thus COPI may indirectly regulate VSV gene expression.  
 LCMV and HPIV3 also replicate in the cytoplasm. LCMV entry occurs by 
receptor-mediated endocytosis whereas HPIV3 enters by fusion of the viral envelope 
with the host cell plasma membrane that is independent of endosomal function. So, the 
effect of COPI depletion on early stage of HPIV3 infection rules out the possibility that 
COPI affect entry of HPIV3. However, LCMV entry also could be mediated by COPI 
function.  Drug treatment (BFA, GCA and AG1478) experiments suggest a role of COPI 
in gene expression of LCMV and HPIV3 which is independent of effect of COPI on 
133 
 
endosome or glycoprotein processing. Moderate effect on VSV gene expression was 
observed when ARF1 was silenced whereas HPIV3 gene expression remained insensitive 
to ARF1 depletion in our experimental setting. We also observed moderate inhibition of 
ARF1 protein expression after knockdown of ARF1. Multiple ARF proteins exist in the 
cell and it is possible that depletion of ARF1 function can be complemented by other 
ARF proteins. Further experiments are required to probe in detail the mechanism of COPI 
requirements for LCMV and HPIV3 replication.  
 Though multiple siRNA screens have identified COPI complex as a host cofactor 
for influenza virus infection (Brass et al., 2009; Karlas et al.,2010; Konig et al.,2010), 
these studies differ in their conclusion regarding role of COPI in influenza virus 
infection. One study has pointed out the role of COPI in HA protein surface expression 
(Brass et al., 2009), whereas another study has suggested a role of COPI in influenza 
entry (Konig et al.,2010). The discrepancies in their results might be due to types of assay 
used. However, for cytoplasmic replicating negative strand virus such as VSV, our results 
point towards a role of COPI in RNA synthesis. It is not clear however, whether COPI 
functions are directly required for VSV RNA transcription and/or replication or are 
required to maintain stability of transcripts and genome.  
To conclude, this study provided a resource to explore further the role of the 
candidate cellular proteins in VSV infection. It is further expected that this resource will 
serve as a meaningful starting point for investigators studying virus-host interaction not 
only for VSV, but also for other negative strand RNA viruses such as LCMV and HPIV3. 
Mechanistic understanding of involvement of these host factors in VSV infection will 
illuminate potential new therapeutic targets against viral diseases.  
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Chapter VI 
SUMMARY AND CONCLUSION 
Viruses utilize the host factors to complete their life cycle. Using VSV as a model 
pathogen studies reported in this dissertation have identified several unique host factors 
required for VSV infection. Future studies may unravel the mechanistic involvement of 
these host factors in VSV replication and gene expression. The following conclusions can 
be derived from these studies.  
1. Expression of VSV replication proteins is not toxic for the cells and a cell line  
stably expressing replication proteins can be generated 
 VSV M has been implicated for the cytopathic effects of VSV. However M 
protein deletion mutant viruses also exert cytopathic effects suggesting involvement of 
other viral proteins. This study showed that expression of replication proteins of VSV 
such as N, P and L has no adverse effect on cell viability. A stable cell line expressing N, 
PeGFP and L could be established and maintained in culture for at least three months 
without loss of the replication functions of the proteins. Functionality of these proteins 
expressed in the stable cell line was evidenced by efficient replication of DI particle 
genome.  
2. Long term replication of DI genome or sub-genomic replicon in stable helper cell  
line could not be established  
We were interested in establishing a replicon system for VSV sub genomic 
replicon.  Maintenance of DI particle genome in the stable helper cell line on long term 
basis was not successful. After 5
th
 passage the cells lost the DI particle genome. This 
study could not establish a cell line supporting replication of a subgenomic replicon of 
VSV with a drug resistant marker.  
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3. Replication of DI genome activates IFN signaling 
While investigating the reasons for failure to establish a long term DI genome 
replicating cell line, we found that DI particle replication in these helper cell line 
activated IFN response.  Activated IFN response was observed in cells replicating DI 
RNA but not in cells cured of DI RNA genome. However, this cell line provided us a 
unique tool to examine genome replication dependent IFN activation. We further showed 
that not mere entry but the replication of DI RNA genome activates IFN response. It has 
been reported previously that rhabdovirus genomic RNAs (VSV and rabies virus) induce 
IFN in replication-independent manner (Hornung et al., 2006; Pichlmair et al., 2006).  
VSV DI genomes are synthesized in the form of nucleocapsid wrapped by the N protein 
and possible formation of dsRNA structures in infected cells has not been reported. The 
mechanism by which VSV DI RNA replication activates IRF3 and NFκB is unknown at 
this time.  
4. Genome wide siRNA screen identified host proteins required for VSV infection 
To identify the host proteins influencing VSV infection, we conducted a genome 
wide siRNA screen approach. So far there has not been such report identifying host genes 
implicated in VSV infection. Functional genomics approach identified host genes in an 
unbiased manner. Several novel candidates were identified in this screen. Our screen also 
identified several known regulators of VSV infection lending further support about 
strength of our screen. These results provide a strong platform to develop a 
comprehensive virus-host interaction map for VSV.  
5. Host COPI complex is involved VSV RNA synthesis 
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 This study identified involvement of COPI in early stage of VSV infection. 
Further experiments suggested a role of COPI in early stage of VSV infection and the 
effect is independent of VSV G protein processing and infectious virus production. To 
further dissect the role of COPI in VSV entry and gene expression, we transfected 
functional nucleocapsids to COPI depleted cells. Nucleocapsids are functional units for 
VSV gene expression and the transfection of nucleocapsids also bypasses the endosome 
mediated entry and uncoating steps of VSV. Nucleocapsid transfection experiments 
confirmed a role of COPI in VSV RNA synthesis. Pharmacological inhibitors of COPI 
also revealed a role of COPI in VSV RNA synthesis.  
 6. COPI is involved in RNA synthesis of LCMV and HPIV3 
To further examine possible involvement of COPI in other cytoplasmic 
replicating RNA viruses, we used LCMV and HPIV3. We showed that, similar to VSV, 
early stage of LCMV and HPIV3 infection also depends on COPI function. It remains to 
be determined whether COPI regulates RNA synthesis for these viruses or not.  
Nevertheless, these results suggest a conserved function of host COPI in cytoplasmic 
replicating negative strand RNA viruses.   
7. ARF1 and GBF1 mediated COPI assembly is required for VSV RNA synthesis  
 ARF1 and GBF1 are upstream regulators of COPI function. Upon activation, 
ARF1 mediates assembly of a preformed COPI complex onto Golgi membrane. When we 
reduced ARF1 expression by siRNA and subsequently infected with VSV, we found a 
moderate inhibition of VSV RNA synthesis. Furthermore, a dominant negative mutant of 
ARF1 also inhibited VSV RNA synthesis. These results suggest that ARF1-regulated 
COPI function is required for VSV RNA synthesis. GBF1 is the guanine nucleotide 
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exchange factor for ARF1. Our results also revealed a role of GBF1 in VSV RNA 
synthesis. Collectively GBF1-ARF1-COPI pathway regulates VSV RNA synthesis.  
8. COPI is not a part of VSV replication complex 
Positive strand RNA viruses replicate in association with double membrane 
vesicles. Some of the positive strand RNA viruses require COPI complex for formation 
of their replication complex. Because ARF1, GBF1 and COPI play critical roles in 
formation of replication complexes for positive strand RNA viruses, we examined their 
possible involvement in VSV replication complex formation. In contrast to positive 
strand RNA viruses, ARF1, GBF1and COPI did not co-localize with VSV replication 
complex.  The sub-cellular distribution of these proteins also did not change following 
VSV infection compared to non-infected cells. These results suggest that COPI may not 
be involved directly in VSV replication complex assembly. Further studies addressing 
downstream effectors of COPI functions will be needed to have a better and mechanistic 
understanding of the involvement of COPI in VSV and other negative-strand RNA virus 
replication.  
9. Integrated model of VSV-host interaction  
 Based on the results obtained in this dissertation, I propose an integrated model of 
VSV-host interaction (Fig. 6.1). The candidate genes were placed at the positions most 
likely relevant to VSV lifecycle. The annotations were gathered from Entrez Gene and 
Uniprot and refined by manual examination of gene functions using Entrez Pubmed. Host 
factors required for all three viruses are identified in green whereas host factors required 
by VSV are shown in red.  
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Figure 6.1: Integrated model of VSV-host interactions  
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